How many Ranibizumab clinical trials are there?

480 Ranibizumab clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 10 are actively recruiting participants. 328 are marked completed.

Are Ranibizumab clinical trials recruiting in 2026?

Yes — 10 Ranibizumab trials are actively recruiting in 2026, with 83 U.S. sites across 26 states. See the recruiting trials and the per-state site list further down this page.

What conditions is Ranibizumab being studied for?

Ranibizumab is being studied for Diabetic Macular Edema, Macular Edema, Macular Degeneration, Age Related Macular Degeneration, Choroidal Neovascularization and 199 more. The trials are grouped by indication on this page.

What phase is Ranibizumab in?

Ranibizumab clinical trials span 96 Phase 4, 110 Phase 3, 95 Phase 2, 42 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.

Who sponsors Ranibizumab clinical trials?

The lead sponsor across the most Ranibizumab trials is Novartis Pharmaceuticals, with 251 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Ranibizumab Clinical Trials (2026): 480 Studies for Diabetic Macular Edema & Macular Edema

Creator: Hipa.ai Research
Published: 2026-06-02T16:35:50.554Z

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: July 17, 2026.

480 Ranibizumab clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 135 indications (including Diabetic Macular Edema & Macular Edema) and 117,012 total planned enrollment. 110 Phase 3 Ranibizumab trials and 95 Phase 2, 96 Phase 4 are listed. 10 Ranibizumab clinical trials are actively recruiting at 83 U.S. sites across 26 states. Most recent activity: NCT07007065 (Mar 2033).

Where to Participate: All Ranibizumab Trial Sites in the U.S. (83 sites across 26 states)

Every actively recruiting Ranibizumabtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

State	Facility	City	Trial	Map
AZ	Barnet Dulaney Perkins Eye Center	Mesa85206-2747	NCT04853251	Map
AZ	Barnet Dulaney Perkins Eye Centers /ID# 279265	Mesa85206	NCT07007065	Map
AZ	American Vision Partners /ID# 264615	Sun City85351	NCT07007065	Map
CA	Retinal Diagnostic Center /ID# 263054	Campbell95008	NCT07007065	Map
CA	The Retina Partners /ID# 263265	Encino91436	NCT07007065	Map
CA	Retina Associates of Southern California	Huntington Beach92647	NCT04853251	Map
CA	Retina Associates of Southern California /ID# 263056	Huntington Beach92647	NCT07007065	Map
CA	Northern California Retina Vitreous Associates - Mountain View /ID# 263990	Mountain View94040-4119	NCT07007065	Map
CA	Retina Consultants of San Diego /ID# 264026	Poway92064-2530	NCT07007065	Map
CA	Retina Consultants Of Southern California - Redlands /ID# 276496	Redlands92374	NCT07007065	Map
CA	Kaiser Permanente - Riverside Medical Center /ID# 263253	Riverside92505	NCT07007065	Map
CA	Retinal Consultants - Sacramento - Greenback Lane /ID# 263983	Sacramento95841	NCT07007065	Map
CA	Retinal Consultants Med Group	Sacramento95841-2013	NCT04853251	Map
CA	UCSF, Wayne and Gladys Valley Center for Vision /ID# 263058	San Francisco94143-2510	NCT07007065	Map
CA	University of California San Francisco	San Francisco94158-2510	NCT04853251	Map
CA	Orange County Retina Med Group	Santa Ana92705-6504	NCT04853251	Map
CA	Orange County Retina Medical Group /ID# 266612	Santa Ana92705	NCT07007065	Map
CA	Macula Retina Vitreous Research Institute	Torrance90503-3270	NCT04853251	Map
CO	Retina Consultants of Southern Colorado /ID# 263284	Colorado Springs80909	NCT07007065	Map
CO	Colorado Retina Associates /ID# 263247	Lakewood80228	NCT07007065	Map
CO	Advanced Vision Research Institute	Longmont80503-6499	NCT04853251	Map
CO	Advanced Vision Surgery Center /ID# 264208	Longmont80503	NCT07007065	Map
FL	Advanced Research, LLC /ID# 276526	Deerfield Beach33064-1346	NCT07007065	Map
FL	Segal Drug Trials, Inc /ID# 276966	Delray Beach33484	NCT07007065	Map
FL	Retina Vitreous Consultants LLP business DBA as Retina Group of Florida /ID# 264631	Fort Myers33917	NCT07007065	Map
FL	Florida Retina Institute - Lake Mary /ID# 263288	Lake Mary32746	NCT07007065	Map
FL	Retina Specialty Institute	Pensacola32503-2030	NCT04853251	Map
FL	Retina Vitreous Associates of Florida	St. Petersburg33711-1141	NCT04853251	Map
FL	Center for Retina and Macular Disease /ID# 264201	Winter Haven33880	NCT07007065	Map
GA	Southeast Retina Center	Augusta30909-6440	NCT04853251	Map
GA	Southeast Retina Center /ID# 263264	Augusta30909	NCT07007065	Map
IL	University Retina and Macula Associates, PC	Lemont60439-7421	NCT04853251	Map
IL	Vision Medical Research /ID# 277102	Oak Lawn60453	NCT07007065	Map
IL	Springfield Clinic Main Campus /ID# 265202	Springfield62703-2403	NCT07007065	Map
IN	Midwest Eye Institute North Indianapolis /ID# 264031	Carmel46290	NCT07007065	Map
IA	Wolfe Eye Clinic - West Des Moines /ID# 263270	West Des Moines50266	NCT07007065	Map
ME	Maine Eye Center	Portland04101	NCT04853251	Map
ME	Maine Eye Center - Marginal Way Campus /ID# 263251	Portland04101	NCT07007065	Map
MD	The Retina Care Center	Baltimore21209-2219	NCT04853251	Map
MD	The Retina Care Center /ID# 263263	Baltimore21209	NCT07007065	Map
MD	Wilmer Eye Institute Johns Hopkins University	Baltimore21287-0005	NCT04853251	Map
MD	Retina Specialist /ID# 264633	Towson21204	NCT07007065	Map
MI	Associated Retinal Consultants /ID# 263289	Royal Oak48073	NCT07007065	Map
MI	Associated Retinal Consultants PC	Royal Oak48073	NCT04853251	Map
MN	Retina Consultants of Minnesota (RCM) - Edina Retina Clinic /ID# 279427	Edina55435	NCT07007065	Map
MN	VitreoRetinal Surgery, PLLC.	Minneapolis55435-3004	NCT04853251	Map
MN	Mayo Clinic - Minnesota /ID# 263977	Rochester55905	NCT07007065	Map
MO	Retina Institute - St. Louis /ID# 263985	St Louis63128	NCT07007065	Map
NV	Sierra Eye Associates	Reno89502-1605	NCT04853251	Map
NJ	Envision Ocular, LLC	Bloomfield07003	NCT04853251	Map
NJ	Monmouth Retina Consultants /ID# 279252	Little Silver07739	NCT07007065	Map
NY	Seeta Eye Centers	Poughkeepsie12603-2416	NCT04853251	Map
NC	Duke Eye Center	Durham27705-4699	NCT04853251	Map
NC	Graystone Eye	Hickory28602	NCT04853251	Map
ND	Fargo Retina Consultants	Fargo58047	NCT04853251	Map
OH	Cincinnati Eye Institute	Blue Ash45242-5537	NCT04853251	Map
OH	Cleveland Clinic	Cleveland44195	NCT04853251	Map
OH	Cleveland Clinic - Cleveland /ID# 264210	Cleveland44195	NCT07007065	Map
OH	Ohio State Havener Eye Institute - Columbus /ID# 263987	Columbus43212	NCT07007065	Map
OH	Midwest Retina /ID# 263231	Dublin43016	NCT07007065	Map
PA	Erie Retina Research /ID# 263287	Erie16507	NCT07007065	Map
PA	Mid Atlantic Retina /ID# 263291	Philadelphia19107	NCT07007065	Map
SC	Charleston Neuroscience Institute - Bluffton /ID# 264037	Bluffton29910	NCT07007065	Map
SC	Charleston Neuroscience Institute - Charleston /ID# 276425	Charleston29414	NCT07007065	Map
SC	Retina Consultants of South Carolina - Ladson /ID# 277596	Ladson29456	NCT07007065	Map
SC	Retina Consultants of America /ID# 264038	Mt. Pleasant29464	NCT07007065	Map
TN	Charles Retina Institute	Germantown38138-2405	NCT04853251	Map
TN	Tennessee Retina PC	Nashville37203-1596	NCT04853251	Map
TX	Retina Research Institute of Texas /ID# 263233	Abilene79606	NCT07007065	Map
TX	Austin Clinical Research, LLC	Austin78750-2298	NCT04853251	Map
TX	Austin Clinical Research, LLC /ID# 263229	Austin78750-2298	NCT07007065	Map
TX	Austin Retina Associates - Austin /ID# 266770	Austin78705	NCT07007065	Map
TX	Retina Consultants of Texas	Bellaire77401	NCT04853251	Map
TX	Star Retina /ID# 266386	Burleson76028	NCT07007065	Map
TX	Retina Consultants of Texas /ID# 263274	Houston77056-3030	NCT07007065	Map
TX	Austin Retina Associates - Round Rock /ID# 266776	Round Rock78681	NCT07007065	Map
TX	Retina Consultants of Texas - Westover /ID# 264209	San Antonio78251	NCT07007065	Map
TX	Retina Consultants of Texas	Schertz78154	NCT04853251	Map
UT	Rocky Mountain Retina Consultants /ID# 263266	Murray84107	NCT07007065	Map
UT	Retina Associates of Utah, PLLC	Salt Lake City84107-6767	NCT04853251	Map
VA	Piedmont Eye Center	Lynchburg24502-4271	NCT04853251	Map
VA	Wagner Kapoor Institute	Norfolk23502-3933	NCT04853251	Map
WA	Spokane Eye Clinical Research	Spokane99204	NCT04853251	Map

Ranibizumab clinical trials at a glance: phase × recruitment status

Phase	recruiting	active not recruiting	completed	terminated	withdrawn	unknown	Total
Early P1			2			1	3
P1			33	1	6	2	42
P1/P2		1	34	2	2	5	44
P2	1	1	71	10	5	7	95
P2/P3		3	9	2	2	7	23
P3	6	4	77	6	3	14	110
P4	1		59	5	6	25	96
N/A	2	1	43	3	2	16	67

Recruiting Ranibizumab clinical trials (10)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

NCT ID	Title	Phase	Indication	Enrollment	Started
NCT07007065	Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)	P3	Neovascular Age-related Macular Degeneration	561	Nov 2025
NCT03683251	PortalExtension Study for the Port Delivery System With Ranibizumab (Portal)	P3	Neovascular Age-Related Macular Degeneration	1,000	Sep 2018
NCT05562947	HUTONGA Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD)	P3	Neovascular Age-related Macular Degeneration	68	Jun 2024
NCT07249216	M-VIVAIdentification of Molecular Signals in Vitreous Humor Associated With Suboptimal Response to Vascular Endothelial Growth Factor (VEGF) Inhibition in Neovascular Age-related Macular Degeneration (nAMD) Within a Clinical Trial Setting	N/A	Age Related Macular Degeneration	117	Jul 2025
NCT06847542	SightspireA Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD	P3	Neovascular Age-related Macular Degeneration	250	Nov 2025
NCT04853251	BelvedereA Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)	P4	Neovascular Age-related Macular Degeneration	188	Dec 2021
NCT03161652	Effect of Levosulpiride on Retinal Alterations in Patients With Diabetic Retinopathy and Diabetic Macular Edema	P2	Diabetic Macular Edema	120	May 2017
NCT07520045	Biomarkers in Diabetic Retinopathy Treated With Faricimab vs Biosimilar Ranibizumab	N/A	Diabetic Retinopathy (DR)	100	Mar 2026
NCT06952452	AMDPharmacogenomics of antiVEGF in Patients With Age-Associated Macular Degeneration (AMD)	P3	Wet Age-related Macular Degeneration	630	Nov 2022
NCT06305416	A Efficacy and Safety Study of Ranibizumab 10mg/ml Injection (Incepta) in Patients With Diabetic Macular Edema	P3	Diabetic Macular Edema	70	Mar 2024

Ranibizumab clinical trials by indication

Diabetic Macular Edema (60)

NCT	Acronym	Phase	Status	Title
NCT04108156	Pagoda	P3	active not recruiting	A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME
NCT03161652	—	P2	recruiting	Effect of Levosulpiride on Retinal Alterations in Patients With Diabetic Retinopathy and Diabetic Macular Edema
NCT06305416	—	P3	recruiting	A Efficacy and Safety Study of Ranibizumab 10mg/ml Injection (Incepta) in Patients With Diabetic Macular Edema
NCT05151731	RO7200220	P2	completed	A Study to Investigate Vamikibart (RO7200220) in Diabetic Macular Edema
NCT05861466	—	P4	completed	Comparative Study Between IVI of Ranibizumab with and Without Prior ACP in Patients with DME Using OCT-A
NCT05151744	RO7200220	P2	completed	A Study to Investigate Vamikibart (RO7200220) in Combination With Ranibizumab in Diabetic Macular Edema
NCT06205979	—	Early P1	unknown	Relationship Between Dyslipidemia and The Response of Diabetic Macular Edema to Intravitreal Injection of Anti Vascular Endothelial Growth Factor Agents
NCT03832179	STAMP	P4	completed	Steroid vs. Anti-vascular Endothelial Growth Factor for Diabetic Macular Edema Prior to Phacoemulsification
+ 52 more, see All trials below.

Macular Degeneration (33)

NCT	Acronym	Phase	Status	Title
NCT04567303	BURGUNDY	P1/P2	active not recruiting	Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration
NCT03805100	XPLORE	P3	completed	Comparing the Efficacy and Safety of Biosimilar Candidate Xlucane Versus Lucentis® in Patients With nAMD
NCT02462928	CEDAR	P3	completed	A Safety and Efficacy Study of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration
NCT02462486	—	P3	completed	Safety and Efficacy of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration
NCT02510794	LADDER	P2	completed	Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration
NCT01213667	RESPONSE	P4	unknown	Genetics in Non-response to Anti-VEGF Treatment in Exudative AMD
NCT01748292	T-REX	P3	completed	Treat & Extend Treatment With 0.5mg Ranibizumab vs Monthly Treatment With 0.5mg Ranibizumab
NCT01006538	MERLOT	P4	completed	Macular EpiRetinal Brachytherapy Versus Lucentis® Only Treatment (MERLOT)
+ 25 more, see All trials below.

Age Related Macular Degeneration (27)

NCT	Acronym	Phase	Status	Title
NCT07249216	M-VIVA	N/A	recruiting	Identification of Molecular Signals in Vitreous Humor Associated With Suboptimal Response to Vascular Endothelial Growth Factor (VEGF) Inhibition in Neovascular Age-related Macular Degeneration (nAMD) Within a Clinical Trial Setting
NCT04740671	—	P3	completed	A Phase 3 Study to Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD
NCT03056092	COVERT	P4	unknown	Cytokine and Visual Outcome Variations in Eyes Receiving Ranibizumab
NCT02174211	VITCLEAR	N/A	completed	A Pharmacokinetic Study: Ranibizumab, Aflibercept and the Effect of Vitrectomy.
NCT02218177	—	N/A	completed	Intraocular Cytokines in Non-responders to Ranibizumab Treatment for Neovascular AMD
NCT02296567	—	P2/P3	unknown	Comparison of Pharmacokinetics of and Effect on Systemic VEGF Levels in Age Related Macular Degeneration Patients
NCT01914159	RIP	P2	completed	Ranibizumab In Pigment Epithelium Tears Secondary To Age-Related Macular Degeneration Study
NCT00593450	—	P3	completed	Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial
+ 19 more, see All trials below.

Neovascular Age-related Macular Degeneration (20)

NCT	Acronym	Phase	Status	Title
NCT07007065	—	P3	recruiting	Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
NCT05562947	HUTONG	P3	recruiting	A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD)
NCT06847542	Sightspire	P3	recruiting	A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD
NCT05476926	VOYAGER	N/A	active not recruiting	A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products
NCT04853251	Belvedere	P4	recruiting	A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)
NCT04757610	ShORe	P3	terminated	OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD)
NCT05461339	nAMD	P3	active not recruiting	TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration
NCT06190093	AMD	P3	completed	A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
+ 12 more, see All trials below.

Macular Edema (20)

NCT	Acronym	Phase	Status	Title
NCT04601675	DME	N/A	unknown	Diabetic Macular Edema (DME) Treatment With Ranibizumab and Dexamethasone or Ranibizumab Only.
NCT03261635	—	P4	completed	Ranibizumab Plus Indomethacin
NCT01827722	ORION	P4	unknown	Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion
NCT02698566	PFS	P3	completed	A Study in Patients With Neovascular Age Related Macular Degeneration or Macular Edema Secondary To Retinal Vein Occlusion to Evaluate Usability of the Ranibizumab (Lucentis®) Prefilled Syringe (PFS)
NCT02169648	—	N/A	unknown	Development of Intravitreal Ranibizumab by Determining the Pathogenesis of Macular Edema With Retinal Vein Occlusion
NCT02186119	—	P2	completed	A Study of Abicipar Pegol in Patients With Diabetic Macular Edema
NCT02032173	CONSTELLATION	P3	terminated	Efficacy and Safety of Lucentis® Use in Patients With Diabetic Macular Edema Evaluating a Spaced Out Follow-up After Intensive Treatment Phase
NCT01535261	CRYSTAL	P3	completed	Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion
+ 12 more, see All trials below.

Age-related Macular Degeneration (20)

NCT	Acronym	Phase	Status	Title
NCT03834753	AMD	P3	completed	A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
NCT03844074	AMD	P3	completed	A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
NCT02140151	PREVENT	P1/P2	completed	Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration
NCT02864472	—	P4	unknown	Comparison of PDT Combination With Ranibizumab vs. Ranibizumab Monotherapy in Persistent PCV With Initial Loading Dose
NCT02302989	PROTECT	P1/P2	completed	Prophylactic Ranibizumab for Exudative Age-Related Macular Degeneration
NCT02707575	—	N/A	completed	Cytokeratin 8 Level in Age-related Macular Degeneration
NCT02727881	MAKO	P3	unknown	Efficacy and Safety Study of Squalamine Ophthalmic Solution in Subjects With Neovascular AMD
NCT01846273	EVEREST II	P4	completed	Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV) Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy (vPDT)
+ 12 more, see All trials below.

Choroidal Neovascularization (20)

NCT	Acronym	Phase	Status	Title
NCT03042871	SMILE	P4	completed	Dosing Strategy of Intravitreal Ranibizumab for Pathological Myopia Choroidal Neovascularization
NCT02484690	AVENUE	P2	completed	A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)
NCT03393767	—	P4	completed	Time Course of Activity Signs at SD-OCT High Frequency Intravitreal Ranibizumab Treatment in CNV Due to AMD
NCT02358889	EMERGE	P2	completed	Study Evaluating Intravitreal hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
NCT01908816	ECLIPSE	P3	completed	An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases.
NCT03409250	—	P4	completed	SD-OCT-guided Intravitreal Ranibizumab Treatment in Choroidal Neovascularization Due to Myopia
NCT01445899	MATISSE	P2	completed	PF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With/Without Ranibizumab in Diabetic Macular Edema (DME)
NCT00570193	PBS	P1/P2	completed	Photodynamic and Pharmacologic Treatment of CNV
+ 12 more, see All trials below.

Diabetic Retinopathy (19)

NCT	Acronym	Phase	Status	Title
NCT04503551	PAVILION	P3	completed	A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm
NCT05248334	—	P1	unknown	A Prospective Study of Ranibizumab in the Treatment of Postoperative Recurrent Vitreous Haemorrhage of Diabetic Retinopathy
NCT05138029	—	P3	unknown	Study on Precision Treatment of Diabetic Retinopathy Macular Edema Guided by Real-time OCT During Operation
NCT03452657	DR	P3	unknown	Multicenter Clinical Study of Anti-VEGF Treatment on High Risk Diabetic Retinopathy (DR)
NCT02366468	DIVERSE	P4	completed	Study of Efficacy of Ranibizumab in Different Regimens in Patients With Diabetic Macula Edema
NCT01476449	—	P2	completed	Dosing Study of Ranibizumab for Diabetic Retinal and Macular Edema
NCT02647515	—	P4	completed	Intravitreal Ranibizumab Injection as Adjuvant in the Treatment of Postvitrectomy Diabetic Vitreous Hemorrhage Accompanied by Neovascular Glaucoma
NCT00444600	LRT for DME	P3	completed	Laser-Ranibizumab-Triamcinolone for Diabetic Macular Edema
+ 11 more, see All trials below.

Age-Related Macular Degeneration (19)

NCT	Acronym	Phase	Status	Title
NCT03725501	—	P2	completed	Evaluation of the Safety and Efficacy of ALS-L1023 Administered in Combination With Ranibizumab in Patients With Wet-AMD
NCT03150589	AMD	P3	completed	A Study to Compare SB11 (Proposed Ranibizumab Biosimilar) to Lucentis in Subjects With Neovascular Age-related Macular Degeneration (AMD)
NCT02130024	RIVAL	P4	completed	A Comparison of Ranibizumab and Aflibercept for the Development of Geographic Atrophy in (Wet) AMD Patients
NCT02387957	—	P2	terminated	A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)
NCT01940900	E10030	P3	terminated	A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy
NCT01944839	E10030	P3	terminated	A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy
NCT02511613	—	P2	withdrawn	Effect of Squalamine Lactate Ophthalmic Solution, 0.2% in Subjects With Neovascular Age-Related Macular Degeneration
NCT01162746	—	P2	completed	Comparison of Ranibizumab Monotherapy and Ranibizumab Combination Therapies in Recurrent or Persistent Choroidal Neovascularization Secondary to Age-related Macular Degeneration
+ 11 more, see All trials below.

Retinal Vein Occlusion (14)

NCT	Acronym	Phase	Status	Title
NCT04140448	UWFA-RVO-ME	N/A	unknown	Ultra-wide-field Fluorescein Angiography in Patients With Macular Edema Secondary to Retinal Vein Occlusion
NCT04062370	—	P4	unknown	Ranibizumab Treatment for Macular Edema Secondary to Retinal Vein Occlusion
NCT02140411	—	P4	completed	Efficacy and Safety of Lucentis® (Ranibizumab Intravitreal Injections) in Chilean Patients With Diabetic Macular Edema.
NCT01428388	CRAVE	N/A	completed	Bevacizumab Versus Ranibizumab in Treatment of Macular Edema From Vein Occlusion
NCT01581151	—	N/A	unknown	Ozurdex With Rescue Lucentis for Treating Macular Edema Secondary to Retinal Vein Occlusion
NCT01003106	RELATE	P1/P2	completed	Ranibizumab DosE Comparison and the Role of LAser in REtinal Vein Occlusions
NCT02614937	—	P1/P2	completed	Study of Squalamine Lactate for the Treatment of Macular Edema Related to Retinal Vein Occlusion
NCT01427751	—	P4	completed	Safety and Efficacy Study of Ozurdex® Compared to Lucentis® in Patients With Branch Retinal Vein Occlusion
+ 6 more, see All trials below.

Proliferative Diabetic Retinopathy (12)

NCT	Acronym	Phase	Status	Title
NCT04464694	—	P4	unknown	Pre-vitrectomy Intravitreal Ranibizumab for Patients With Proliferative Diabetic Retinopathy Combined With Diabetic Macular Edema
NCT02447185	aiRTo-PDR	P3	unknown	25-G Vitrectomy With Ranibizumab or Triamcinolone Acetonide on PDR in China-Randomized Clinical Trial
NCT01489189	Protocol S	P3	completed	Prompt Panretinal Photocoagulation Versus Ranibizumab+Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
NCT02857491	—	N/A	completed	Intravitreal Injection of Ranibizumab Versus Sham Before Vitrectomy in Patients With Proliferative Diabetic Retinopathy
NCT02067013	ARK	P2	unknown	Analysis of Aqueous and Vitreous Humor
NCT02328118	RaTAPDR	P2/P3	unknown	25-Gauge Vitrectomy With Ranibizumab or Triamcinolone Acetonide on Proliferative Diabetic Retinopathy in China
NCT00668785	—	P2	terminated	Intravitreal Ranibizumab to Treat Macular Edema After Panretinal Photocoagulation (Phase II)
NCT02005432	IVR	P4	unknown	PASCAL Laser Versus ETDRS Laser Associated With Intravitreal Ranibizumab (IVR) Versus Only IVR for Proliferative Diabetic Retinopathy
+ 4 more, see All trials below.

Branch Retinal Vein Occlusion (9)

NCT	Acronym	Phase	Status	Title
NCT05520177	—	P3	completed	A Phase III Study for 601 Versus Ranibizumab in Patients With Vision Loss
NCT02478515	—	P4	completed	Evaluation of the Usefulness of a PRN Regimen Using Ranibizumab for Macular Edema Due to Branch Retinal Vein Occlusion
NCT03054766	—	N/A	completed	Combination of Intravitreal Ranibizumab With or Without Macular Laser Photocoagulation for ME Secondary to BRVO
NCT01795209	RVOFV	P4	terminated	Ranibizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion in Patients With Fair Vision
NCT01968239	RabOCT	P2	completed	Proof of Concept Study of Re-treatment in BRVO With Ranibizumab Guided by OCT
NCT02527733	—	P4	unknown	Retinal Sensitivity in BRVO After Anti-VEGF Therapy
NCT01599650	BRIGHTER	P3	completed	Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion
NCT01471691	RAVEN	P1/P2	completed	Intravitreal Ranibizumab 0.5MG, or 1.0mg for RVO With Macular Edema Previously Receiving Bevacizumab
+ 1 more, see All trials below.

Wet Macular Degeneration (8)

NCT	Acronym	Phase	Status	Title
NCT04698850	BEY-RAP	P4	withdrawn	Brolucizumab vs. Aflibercept for Retinal Angiomatous Proliferation
NCT03423823	ZEBRA	P2	completed	Ziv-aflibercept Efficacy in Better Regulating AMD
NCT03944070	—	N/A	unknown	Management of Patients With Neovascular Age-related Macular Degeneration Undergoing Cataract Surgery
NCT02806752	RANTA	P4	unknown	Intravitreal Ranibizumab and TA Combination Therapy vs. Ranibizumab Monotherapy in Polypoidal Choroidal Vasculopathy
NCT01243086	STAR	P2	completed	OZURDEX in Age Related Macular Degeneration as Adjunct to Ranibizumab
NCT02060604	—	P4	completed	Pilot Study of Ranibizumab With and Without Ketorolac Eyedrops for Exudative Age-related Macular Degeneration
NCT01189019	HiPED	P2	terminated	HiPED - High Dose Lucentis for Persistent Pigment Epithelial Detachments in Age-related Macular Degeneration
NCT01249937	STAR	P2	unknown	Sub-tenon Triamcinolone Acetonide in Age-Related Macular Degeneration as Adjunct to Ranibizumab

Polypoidal Choroidal Vasculopathy (8)

NCT	Acronym	Phase	Status	Title
NCT04714242	—	N/A	completed	OCTA and Polypoidal Choroidal Vasculopathy
NCT03459144	—	N/A	completed	Comparison of PDT, Intravitreal Ranibizumab and Combination for Polypoidal Choroidal Vasculopathy Under 1+PRN Regimen
NCT01469156	—	P1/P2	completed	Safety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal Vasculopathy
NCT01248117	PEARL2	P1/P2	unknown	Safety Study of High-Dose Ranibizumab for Polypoidal Choroidal Vasculopathy
NCT01360151	—	N/A	unknown	Aqueous Humor Level of Cytokines in Polypoidal Choroidal Vasculopathy and Change of Cytokines After Photodynamic Therapy
NCT00837330	—	P1/P2	completed	Ranibizumab (Lucentis) for Polypoidal Choroidal Vasculopathy
NCT00424710	PEARL	P1	completed	Ranibizumab for Polypoidal Choroidal Vasculopathy (PCV)
NCT00674323	PCV	P4	completed	Efficacy and Safety of Verteporfin Added to Ranibizumab in the Treatment of Symptomatic Macular Polypoidal Choroidal Vasculopathy

Neovascular Age-Related Macular Degeneration (7)

NCT	Acronym	Phase	Status	Title
NCT03683251	Portal	P3	recruiting	Extension Study for the Port Delivery System With Ranibizumab (Portal)
NCT05126966	Diagrid	P3	withdrawn	A Study Of The Effectiveness And Safety Of A 36-Week Refill Regimen For The Port Delivery System With Ranibizumab Vs Aflibercept Treat & Extend In Subjects With Neovascular Age-Related Macular Degeneration
NCT04662944	RAZORBILL	N/A	completed	A Non-interventional Study to Assess the Influence of Automated Optical Coherence Tomography Image Enrichment With Segmentation Information on Disease Activity Assessment in Patients Treated With Licensed Anti- VEGF Injections
NCT03677934	Archway	P3	completed	A Phase III Study to Evaluate the Port Delivery System With Ranibizumab Compared With Monthly Ranibizumab Injections in Participants With Wet Age-Related Macular Degeneration
NCT02530918	—	P1	completed	Study of DS-7080a for the Treatment of Macular Degeneration
NCT01926977	—	P1/P2	completed	Evaluation of Pain and Inflammation After Injection of Lucentis vs Eylea for Treatment of Wet Macular Degeneration
NCT00344227	—	P2	completed	Prospective OCT Study With Lucentis for Neovascular AMD (PrONTO Study)

Central Retinal Vein Occlusion (7)

NCT	Acronym	Phase	Status	Title
NCT02274259	—	P4	completed	Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With CRVO With a Treat& Extend Regimen
NCT01976312	Camellia	P3	completed	Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO)
NCT02091505	CRVO	N/A	unknown	Predictive Factors of Ranibizumab Treatment in Macular Edema With CRVO
NCT01448018	CHIC-3	P4	completed	Hemodilution Versus Ranibizumab in Early-onset Central Retinal Vein Occlusion
NCT01028248	—	P1	completed	Lucentis for Macular Edema Associated With Central Retinal Vein Occlusion
NCT00406796	CRVO	P1	completed	Lucentis for Central Retinal Vein Occlusion (CRVO)
NCT00567697	—	P3	completed	A Randomized Study Comparing Ranibizumab to Sham in Patients With Macular Edema Secondary to CRVO

Glaucoma (6)

NCT	Acronym	Phase	Status	Title
NCT02641457	—	P3	completed	Intravitreal Aflibercept or Ranibizumab for Rubeosis Iridis
NCT00661583	OCTOPUS	P1/P2	completed	Use of Ranibizumab With Mitomycin C During Trabeculectomy
NCT00892398	—	N/A	completed	Trabeculectomy With Mitomycin C Associated With Sub-conjunctival Injection of Ranibizumab
NCT00626782	—	P2/P3	completed	Lucentis Versus Mitomycin C During Glaucoma Surgery
NCT00644280	—	N/A	terminated	Ranibizumab in Preventing Failure of Ahmed Valve Glaucoma Surgery
NCT00727038	NVG	P1/P2	withdrawn	Lucentis for New Onset Neovascular Glaucoma

Exudative Age-related Macular Degeneration (5)

NCT	Acronym	Phase	Status	Title
NCT02976194	CyPov	P4	unknown	Intraocular Cytokine in Recurrence of Polypoidal Choroidal Vasculopathy
NCT02328209	—	N/A	unknown	Evaluation of the Simplified Treat And Extend Regimen Using Ranibizumab in Exudative Age Related Macular Degeneration
NCT01127360	LUCAS	P4	completed	LUCAS (Lucentis Compared to Avastin Study)
NCT01810042	—	P4	completed	Indocyanine Angiographic Changes of Choroidal Neovascularization by Ranibizumab
NCT01500915	FUSION	P4	completed	FUSION Regimen: Combined Pro re Nata and Fixed Regimen Ranibizumab in Exudative Age-related Macular Degeneration

Exudative Age-Related Macular Degeneration (5)

NCT	Acronym	Phase	Status	Title
NCT02355028	—	P2	completed	LHA510 Proof-of-Concept Study as a Maintenance Therapy for Patients With Wet Age-Related Macular Degeneration
NCT01849692	—	P2	completed	ESBA1008 Microvolume Study
NCT01304693	AMD	P1/P2	completed	ESBA1008 Safety, Tolerability and Effects in Wet Age-Related Macular Degeneration (AMD) Patients
NCT00793923	Lucedex	P1/P2	completed	A Prospective Study Comparing Ranibizumab Plus Dexamethasone Combination Therapy Versus Ranibizumab Monotherapy for Wet AMD
NCT01157065	RACE	P2	completed	Evaluation of AL-78898A in Exudative Age-Related Macular Degeneration

Wet Age-related Macular Degeneration (4)

NCT	Acronym	Phase	Status	Title
NCT06952452	AMD	P3	recruiting	Pharmacogenomics of antiVEGF in Patients With Age-Associated Macular Degeneration (AMD)
NCT05480293	IVT	P3	unknown	This Study Will Compare the Efficacy and Safety of SCT510A Administered by Intravitreal Injection (IVT) With Ranibizumab in Patients With wAMD
NCT07389577	—	P3	completed	A Study to Compare JL14002 to Lucentis® in Subjects With Wet Age-related Macular Degeneration (wAMD)
NCT02036723	GALATIR	P3	withdrawn	Safety and Efficacy Study of BCD-021 Compared to Lucentis® in Patients With Neovascular Wet Age-related Macular Degeneration

Retinopathy of Prematurity (4)

NCT	Acronym	Phase	Status	Title
NCT04539106	—	N/A	completed	Intravitreal Ranibizumab in Recurrent ROP
NCT02375971	RAINBOW	P3	completed	RAINBOW Study: RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity
NCT03334513	—	N/A	completed	Refractive Error and Biometry in Retinopathy of Prematurity
NCT02164604	ROP	N/A	completed	Lucentis to Treat Retinopathy of Prematurity (ROP) 3 Plus Disease

Diabetes Mellitus (4)

NCT	Acronym	Phase	Status	Title
NCT03499223	DME	P2	completed	A Study to Evaluate THR-317 and Ranibizumab Combination Treatment for Diabetic Macular Oedema (DME)
NCT02302079	VIDI	P2	completed	A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema (DME)
NCT00473330	RISE	P3	completed	A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RISE)
NCT00473382	RIDE	P3	completed	A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RIDE)

Diabetic Macular Edema (DME) (3)

NCT	Acronym	Phase	Status	Title
NCT06957080	BAROLO	P2/P3	active not recruiting	A Study of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME
NCT06571045	BRUNELLO	P2/P3	active not recruiting	A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME
NCT02050828	TIME-2	P2	completed	The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema

Visual Impairment Due to Diabetic Macular Edema (3)

NCT	Acronym	Phase	Status	Title
NCT02878681	TIDE DME	P4	withdrawn	24 Week Study to Compare Systemic VEGF-levels of Ranibizumab and Aflibercept in DME.
NCT02258009	TIDE DME	P4	withdrawn	Systemic VEGF Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema
NCT01131585	RELATION	P3	terminated	Safety and Efficacy of Ranibizumab in Diabetic Macular Edema

Radiation Retinopathy (3)

NCT	Acronym	Phase	Status	Title
NCT02222610	RRR	P2	completed	Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation to Treat Radiation Retinopathy.
NCT01334879	—	P1	completed	High Dose Intravitreal Ranibizumab for Recalcitrant Radiation Retinopathy
NCT00750399	—	P1	completed	Effect of Intravitreal Ranibizumab on Radiation Retinopathy Following Plaque Brachytherapy for Choroidal Melanoma

Pterygium (3)

NCT	Acronym	Phase	Status	Title
NCT02342392	—	P2/P3	completed	Intralesional Ranibizumab on Pterygium Vascularity, Size and Recurrence Rate: a Pilot Study
NCT01169909	—	P1	completed	Efficacy and Safety of Sub-tenon Ranibizumab for Recurrent Pterygia
NCT00768963	—	P1	completed	Ranibizumab for the Inhibition of Neovascularization in Pterygia

Visual Impairment (3)

NCT	Acronym	Phase	Status	Title
NCT01396083	COMRADE-C	P3	completed	Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Central Retinal Vein Occlusion (CRVO)
NCT01396057	COMRADE-B	P3	completed	Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Branch Retinal Vein Occlusion (BRVO)
NCT01315275	LUDIC	P4	completed	A Clinical Study in Current Medical Practice of the Efficacy and Safety of Ranibizumab 0.5mg in Diabetic Patients Presenting a Visual Impairment Due to Macular Edema

Choroidal Melanoma (3)

NCT	Acronym	Phase	Status	Title
NCT00765921	—	P1	completed	Ranibizumab in Combination With Proton Beam Irradiation for Choroidal Melanoma
NCT01251978	—	P2	completed	Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)
NCT00680225	—	P3	completed	Lucentis as an Adjuvant Therapy With TTT-ICG Based in Choroidal Melanoma

Neovascular Age Related Macular Degeneration (3)

NCT	Acronym	Phase	Status	Title
NCT00764738	—	P2/P3	completed	Study Investigating OCT, Multifocal ERG, and Microperimetry in Monthly Versus PRN Ranibizumab in Neovascular Age-Related Macular Degeneration
NCT00574093	Luvi	P2	completed	Efficacy and Safety Study of Lucentis (Ranibizumab) and Visudyne (Verteporfin) Combination Therapy in Neovascular AMD
NCT00640640	AMD	N/A	unknown	The Effects of Bevacizumab and Ranibizumab on Ocular Pulse Amplitude in Neovascular Age Related Macular Degeneration (AMD)

Telangiectasia (3)

NCT	Acronym	Phase	Status	Title
NCT00378196	RIPT	P1	completed	Ranibizumab in Idiopathic Parafoveal Telangiectasia (RIPT) Trial
NCT00457145	—	P1	completed	Injected Ranibizumab to Treat Macular Telangiectasia Without New Blood Vessel Formation
NCT00457067	—	P1	completed	Injected Ranibizumab to Treat Macular Telangiectasia With New Blood Vessel Formation

Choroidal Neovascularization Secondary to Pathologic Myopia (2)

NCT	Acronym	Phase	Status	Title
NCT06176352	POYANG	P3	completed	A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia
NCT02034006	OLIMPIC	P3	completed	A Study of the Criteria Establishing the Need for Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia.

Exudative Age Related Macular Degeneration (2)

NCT	Acronym	Phase	Status	Title
NCT04075136	OCTA	P4	withdrawn	Optical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy
NCT03071055	—	P2	completed	Efficacy of Biweekly Ranibizumab (0.5 mg) for Exudative Macular Degeneration Retinal Edema Refractory to Anti-VEGF

Retinopathy of Prematurity Both Eyes (2)

NCT	Acronym	Phase	Status	Title
NCT05033106	—	P3	unknown	Ranibizumab Vs Bevacizumab for Type 1 Retinopathy of Prematurity
NCT03148132	—	P4	completed	VEGF Concentrations After Intravitreal Bevacizumab vs Ranibizumab as a Treatment for Type 1 ROP

Central Retinal Vein Occlusion With Macular Edema (2)

NCT	Acronym	Phase	Status	Title
NCT04444492	CoRaLaII	P3	active not recruiting	Combination of Ranibizumab and Targeted Laser Photocoagulation
NCT02522897	PEARL	P4	unknown	Evaluation of the "Treat-and-extend" Scheme in Patients With Retinal Vein Occlusion (RVO) With and Without LASER Treatment of Ischaemic Retinal Areas

Uveitis (2)

NCT	Acronym	Phase	Status	Title
NCT02623426	MERIT	P3	completed	Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial
NCT00498355	LIME	P1/P2	completed	Lucentis for Inflammatory Macular Edema Trial

Von Hippel-Lindau Syndrome (2)

NCT	Acronym	Phase	Status	Title
NCT02859441	—	P1/P2	completed	A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab
NCT00089765	—	P1	completed	Ranibizumab Injections to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome

Glaucoma, Neovascular (2)

NCT	Acronym	Phase	Status	Title
NCT02914626	—	P3	unknown	Intravitreal Ranibizumab (Lucentis®) for Neovascular Glaucoma- a Randomized Controlled Study
NCT01922154	—	P4	completed	Intravitreous Ranibizumab as Adjunctive Treatment for Trabeculectomy in Neovascular Glaucoma

Retinopathy of Prematurity (ROP) (2)

NCT	Acronym	Phase	Status	Title
NCT02640664	RainbowExt	P3	completed	Rainbow Extension Study
NCT02134457	CARE-ROP	P2	completed	Comparing Alternative Ranibizumab Dosages for Safety and Efficacy in Retinopathy of Prematurity

Age-related Macular Degeneration (AMD) (2)

NCT	Acronym	Phase	Status	Title
NCT02611778	COLUMBUS-AMD	P3	completed	Efficacy and Safety of the Biosimilar Ranibizumab FYB201 in Comparison to Lucentis in Patients With Neovascular Age-related Macular Degeneration
NCT02398500	—	P1/P2	terminated	Safety Tolerability and Efficacy of Intravitreal LMG324 in the Treatment of Neovascular Age-Related Macular Degeneration

Retinal Diseases (2)

NCT	Acronym	Phase	Status	Title
NCT02646670	—	P4	completed	Efficacy of Ranibizumab Therapy With Aflibercept in Patients With Diabetic Macular Edema
NCT01205035	HD-LIPT	P2	completed	High-Dose Lucentis (Ranibizumab 2.0mg) for the Treatment of Nonproliferative Idiopathic Parafoveal Telangiectasia

Diabetic Macula Edema (2)

NCT	Acronym	Phase	Status	Title
NCT02131350	—	P4	completed	Combination Treatment of Intravitreal Ranibizumab, Focal/Grid Laser and Panretinal Photocoagulation in Patients With Diabetic Macula Edema
NCT02462304	END-DME	P4	unknown	To Compare Anti-VEGF Monotherapy With Anti-VEGF and EPM Grid Laser Combination Therapy for Diabetic Macular Edema

Macular Disease (2)

NCT	Acronym	Phase	Status	Title
NCT02321267	—	P4	unknown	Cohort Study of the Clinical Course of Macular Diseases in Kagawa
NCT02081339	—	N/A	unknown	Cohort Study of the Clinical Course of Macular Diseases in Japanese

Diabetic Macular Oedema (2)

NCT	Acronym	Phase	Status	Title
NCT02207712	CANDLE	N/A	terminated	Noctura400 Treatment for Diabetic Retinopathy (CANDLE)
NCT03495765	CONTROL	P3	completed	To Evaluate the Comparative Efficacy of Lucentis (Ranibizumab) 0.5mg Intravitreal Injection in Patients With Diabetic Macular Oedema (DME) With Well Controlled and Poorly Controlled Diabetes Mellitus

Exudative Macular Degeneration (2)

NCT	Acronym	Phase	Status	Title
NCT01835067	TAPAS	P2/P3	completed	Intravitreal tPA and C3F8 for the Treatment of Submacular Haemorrhage as a Complication of Neovascular AMD
NCT01674569	—	P1/P2	completed	Pilot Study of X-82 in Patients With Wet AMD

High Risk Proliferative Diabetic Retinopathy (2)

NCT	Acronym	Phase	Status	Title
NCT01941329	PROTEUS	P2/P3	completed	Prospective, Randomized, Multicentre, Open-label, Phase II / III Study to Assess Efficacy and Safety of Ranibizumab 0.5 mg Intravitreal Injections Plus Panretinal Photocoagulation (PRP) Versus PRP in Monotherapy in the Treatment of Subjects With High Risk Proliferative Diabetic Retinopathy.
NCT01280929	PRP	P2	completed	Prospective, Randomized, Multicenter, Open Label, Phase II Study to Access Efficacy and Safety of Lucentis® Monotherapy Compared With Lucentis® Plus Panretinal Photocoagulation (PRP) and PRP in the Treatment of Patients With High Risk Proliferative Diabetic Retinopathy

Subfoveal Choroidal Neovascularization (2)

NCT	Acronym	Phase	Status	Title
NCT01122511	—	P2	terminated	Safety and Efficacy of Dexamethasone as Adjunctive Therapy to Ranibizumab in Subjects With Choroidal Neovascularization and Age-Related Macular Degeneration
NCT00930189	—	P2/P3	withdrawn	Comparative Study With Photodynamic Therapy And Triamcinolone Versus Photodynamic Therapy, Triamcinolone And Ranibizumab In Patients With Subfoveal Choroidal Neovascularization

Uveal Melanoma (2)

NCT	Acronym	Phase	Status	Title
NCT00811200	TORR	P2/P3	unknown	Treatment Of Radiation Retinopathy Trial
NCT00540930	—	P4	unknown	Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy

Pigment Epithelial Detachment (2)

NCT	Acronym	Phase	Status	Title
NCT00976222	—	P4	completed	Intravitreal Ranibizumab in Retinal Pigment Epithelial Detachments
NCT00841581	—	P2	completed	Lucentis to Treat Pigment Epithelial Detachment

Corneal Neovascularization (2)

NCT	Acronym	Phase	Status	Title
NCT00769145	—	P1	completed	Ranibizumab for the Inhibition of Neovascularization in the Cornea Following Corneal Transplant Surgery
NCT00681889	NV	P1	completed	Effectiveness and Safety of Topical Ranibizumab for Treatment of Corneal Neovascularization (NV)

Age-Related Maculopathy (2)

NCT	Acronym	Phase	Status	Title
NCT00473642	PDT	P4	completed	Reduced Fluence Photodynamic Therapy (PDT) With Visudyne in Combination With Lucentis for Age-Related Macular Degeneration
NCT00056823	AMD	P1/P2	completed	Intravitreal Injections of rhuFab V2 in Combination With Visudyne in Subjects With Age Related Macular Degeneration (AMD)

Diabetic Retinopathy (DR) (1)

NCT	Acronym	Phase	Status	Title
NCT07520045	—	N/A	recruiting	Biomarkers in Diabetic Retinopathy Treated With Faricimab vs Biosimilar Ranibizumab

Macular Cystoid Edema (1)

NCT	Acronym	Phase	Status	Title
NCT06234514	JQMMT+RA	P4	completed	Manage Macular Cystoid Edema With Retinal Vein Obstruction Using Traditional Chinese Medicine and Ranibizumab

Mild Non-proliferative Diabetic Retinopathy (1)

NCT	Acronym	Phase	Status	Title
NCT05386160	—	P4	unknown	Phacoemulsification Combined With Intravitreal Injection of Ranibizumab Prevent Postoperative Capillary Non-perfusion Zone Progress in Non-proliferative Diabetic Retinopathy

Neovascular Age-related Macular Edema (1)

NCT	Acronym	Phase	Status	Title
NCT05222633	—	N/A	unknown	Anti-VEGF in Real-world

Neovascular Age-related Macular Degeneration (nAMD) (1)

NCT	Acronym	Phase	Status	Title
NCT04657289	—	P3	active not recruiting	A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)

Pathological Myopic Choroidal Neovascularization (1)

NCT	Acronym	Phase	Status	Title
NCT04922151	—	P2	unknown	601 Versus Ranibizumab in Patients With Pathological Myopic Choroidal Neovascularization (pmCNV)

Non-Ischemic Central Retinal Vein Occlusion With Macular Edema (1)

NCT	Acronym	Phase	Status	Title
NCT05282420	—	P4	unknown	Ranibizumab Versus Aflibercept for CRVO in Young Patients.

AMD (1)

NCT	Acronym	Phase	Status	Title
NCT04704921	ATMOSPHERE	P2/P3	active not recruiting	Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD

Retina Disease (1)

NCT	Acronym	Phase	Status	Title
NCT05701124	—	P3	completed	Intravitreal Ranibizumab Injection for Aggressive Versus Type 1 Prethreshold Retinopathy of Prematurity

Neovascular Age-Related Macular Degeneration (nAMD) (1)

NCT	Acronym	Phase	Status	Title
NCT04514653	AAVIATE	P2	active not recruiting	RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)

Clinically Significant Macular Edema Due to Diabetes Mellitus (1)

NCT	Acronym	Phase	Status	Title
NCT03999125	—	P4	unknown	Anti-VEGF Therapy Versus Dexamethasone Implant for DME

Ophthalmopathy (1)

NCT	Acronym	Phase	Status	Title
NCT04460001	CRVO	P2/P3	unknown	Injection of Ranibizumab Versus Combination of Ranibizumab and Triamcinolone Acetate for (CRVO)

Branch Retinal Vein Occlusion with Macular Edema (1)

NCT	Acronym	Phase	Status	Title
NCT03709745	—	P4	completed	Eylea and Lucentis for Macular Edema in Branch Retinal Vein Occlusion

Patients With Primary Nasal Pterygium (1)

NCT	Acronym	Phase	Status	Title
NCT04878835	—	P1	completed	Effects of Ranibizumab in Primary Pterygium Surgery

Infant, Premature, Diseases (1)

NCT	Acronym	Phase	Status	Title
NCT03115255	—	N/A	completed	Serum Vascular Endothelial Growth Factor in Infants With Intravitreal Ranibizumab

Diabetic Retinal Edema (1)

NCT	Acronym	Phase	Status	Title
NCT03590444	DME	P4	completed	Treatment of Diabetic Macular Edema (DME) With Anti-VEGF and Focal Laser

Neovascularization, Choroidal (1)

NCT	Acronym	Phase	Status	Title
NCT03038880	STAIRWAY	P2	completed	Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration

Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO) (1)

NCT	Acronym	Phase	Status	Title
NCT02953938	ZIPANGU	P4	completed	Study to Show a Superior Benefit in Terms of Reduction of Ranibizumab Injections in Patients Receiving Ranibizumab Plus Laser Photocoagulation Combination Therapy Without Loss of Efficacy and Safety

Wet Age-related Macular Degeneration (Wet AMD) (1)

NCT	Acronym	Phase	Status	Title
NCT02634970	CANARI	P4	withdrawn	CANadian Study in Patients With Wet AMD, Evaluating the Efficacy and Safety of Switching From Intravitreal Aflibercept to RanIbizumab

Visual Acuity Reduced Transiently (1)

NCT	Acronym	Phase	Status	Title
NCT02665689	DORO	P4	terminated	Influence of Diabetes Control on Treatment of Diabetic Macular Edema With Ranibizumab

Coats Disease (1)

NCT	Acronym	Phase	Status	Title
NCT04310631	—	N/A	completed	Evaluation of Retinal and Vascular Features in Coats Disease After Intravitreal Injections of Ranibizumab

Retinal Dystrophies (1)

NCT	Acronym	Phase	Status	Title
NCT03763227	—	P2	completed	Intravitreal Ranibizumab (Lucentis®) in the Treatment of Non-leaking Macular Cysts in Retinal Dystrophy

Wet Age-Related Macular Degeneration (1)

NCT	Acronym	Phase	Status	Title
NCT02257632	TIDE AMD	P4	completed	Systemic Vascular Endothelial Growth Factor (VEGF) Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Neovascular Age-related Macular Degeneration

Neovascular (Wet) Age-related Macular Degeneration (AMD) (1)

NCT	Acronym	Phase	Status	Title
NCT02243878	STAR	P3	completed	Stereotactic Radiotherapy for Wet AMD (STAR)

CYSTOID MACULAR EDEMA (1)

NCT	Acronym	Phase	Status	Title
NCT02294656	—	P1	completed	Acute Pseudophakic Cystoid Macular Edema Treatment Trial: Intravitreal Ranibizumab Versus Triamcinolone Acetonide

Researcher-Subject Relations (1)

NCT	Acronym	Phase	Status	Title
NCT02144662	—	N/A	completed	Prognostic Factors for Visual Improvement in Patients Undergoing Intravitreal Ranibizumab for Retinal Vein Occlusion

Wet Age Related Macular Degeneration (1)

NCT	Acronym	Phase	Status	Title
NCT01986907	TWEYES	P4	completed	Safety and Tolerability of Ranibizumab in Mono/Bilateral Wet Age Related Macular Degeneration (w-AMD) Patients in Eyes With BCVA<2/10 and/or 2nd Affected Eye

Intraocular Pressure (1)

NCT	Acronym	Phase	Status	Title
NCT02474225	—	N/A	completed	Intraocular Pressure Change Following Intravitreal Injection of Anti-vascular Endothelial Growth Factor Agent

Macular Edema, Diabetic (1)

NCT	Acronym	Phase	Status	Title
NCT01994291	—	P2	terminated	A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema

Macular Edema Secondary to Branch Retinal Vein Occlusion (1)

NCT	Acronym	Phase	Status	Title
NCT01976338	Blossom	P3	completed	Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Branch Retinal Vein Occlusion (BRVO)

Recalcitrant Wet Age-related Macular Degeneration (1)

NCT	Acronym	Phase	Status	Title
NCT01972763	RESCUE	P1/P2	completed	Ranibizumab for Recalcitrant Wet Age-related Macular Degeneration in Eyes Previously Switched From Bevacizumab and/or Ranibizumab to Aflibercept.

Subfoveal Choroidal Neovascularization CNV Secondary to Wet Age-related Macular Degeneration AMD (1)

NCT	Acronym	Phase	Status	Title
NCT01972789	FLUID	P4	completed	Comparison of Treatment Regimens Using Ranibizumab: Intensive (Resolution of Intra- and Sub-retinal Fluid) vs Relaxed (Resolution of Intra-retinal Fluid and/or Sub-retinal Fluid >200µm at the Foveal Centre)

Macular Edema (ME) (1)

NCT	Acronym	Phase	Status	Title
NCT01846299	—	P3	completed	To Assess the Efficacy and Safety of Intravitreal Ranibizumab in People With Vision Loss Due to Macular Edema

Macular Edema Due to BRVO/CRVO (1)

NCT	Acronym	Phase	Status	Title
NCT01968616	—	N/A	unknown	Ranibizumab Treatment for Retinal Vein Occlusion

Choroidal Neovascularization (CNV) (1)

NCT	Acronym	Phase	Status	Title
NCT01840410	—	P3	completed	Assess the Efficacy/Safety of Intravitreal Ranibizumab in Patients With Vision Loss Due to Choroidal Neovascularization.

Visual Impairment Due to Choroidal Neovascularization (CNV) Secondary to Pathologic Myopia (PM) (1)

NCT	Acronym	Phase	Status	Title
NCT01922102	Brilliance	P3	completed	Efficacy and Safety of Ranibizumab 0.5 vs Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia

Ophthalmology (1)

NCT	Acronym	Phase	Status	Title
NCT01771081	POLARIS	N/A	completed	Evaluation of Changes in Visual Acuity in Patients With Diabetic Macular Edema (DME) Starting Treatment With an Approved Anti-VEGF Therapy

Proliferative Diabetic Retinopathy (PDR) (1)

NCT	Acronym	Phase	Status	Title
NCT01594281	PRIDE	P2	completed	Multicenter 12 Months Clinical Study to Evaluate Efficacy and Safety of Ranibizumab Alone or in Combination With Laser Photocoagulation vs. Laser Photocoagulation Alone in Proliferative Diabetic Retinopathy (PRIDE)

Central Retinal, Hemi Retinal & Brach Retinal Vein Occlusions (1)

NCT	Acronym	Phase	Status	Title
NCT01710839	WAVE	P4	completed	Widefield Angiography Guided Targeted-retinal Photocoagulation Combined With Anti VEgf Intravitreal Injections for the Treatment of Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion

Radiation Maculopathy (1)

NCT	Acronym	Phase	Status	Title
NCT04377295	—	N/A	completed	Evaluation of Retinal and Vascular Features in Radiation Maculopathy After Intravitreal Injections of Ranibizumab

Degeneration of Macula and Posterior Pole (1)

NCT	Acronym	Phase	Status	Title
NCT01669447	—	P4	unknown	Evaluation of Changes in the Parameters of Optical Coherence Tomography After Intravitreal Injection of Lucentis

Myopia, Degenerative (1)

NCT	Acronym	Phase	Status	Title
NCT01968486	—	P1	completed	Reduced-fluence Verteporfin Photodynamic Therapy Plus Ranibizumab for Choroidal Neovascularization in Pathologic Myopia

Uveitis Related Cystoid Macular Edema (1)

NCT	Acronym	Phase	Status	Title
NCT01564108	—	P2	completed	The LIMO Study, Lucentis for Treatment of Uveitic Patients With Refractory Cystoid Macular Oedema

Hereditary Hemorrhagic Telangiectasia (HHT) (1)

NCT	Acronym	Phase	Status	Title
NCT01406639	HHT	P1	withdrawn	Ranibizumab for the Management of Recurrent Nosebleeds in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)

Wet Age Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion (1)

NCT	Acronym	Phase	Status	Title
NCT01318941	LUMINOUS	N/A	completed	Observe the Effectiveness and Safety of Ranibizumab in Real Life Setting

PCV (1)

NCT	Acronym	Phase	Status	Title
NCT01884597	PEARL2	P1/P2	completed	Investigator Sponsored Trial of Polypoidal Choroidal Vasculopathy (PCV) Evaluation Assessing High-Dose Ranibizumab Prospectively (PEARL2)

Epiretinal Membrane (1)

NCT	Acronym	Phase	Status	Title
NCT01238393	LERM	N/A	completed	Treatment of Epiretinal Membranes With Ranibizumab

Pathological Myopia (1)

NCT	Acronym	Phase	Status	Title
NCT01217944	—	P3	completed	Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia

Ischemia (1)

NCT	Acronym	Phase	Status	Title
NCT01225146	RAVE2	P1	terminated	Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2)

Diabetes Complications (1)

NCT	Acronym	Phase	Status	Title
NCT01030770	—	P2/P3	completed	Preoperative Intravitreal Ranibizumab for Persistent Diabetic Vitreous Haemorrhage:

Vitreous Hemorrhage (1)

NCT	Acronym	Phase	Status	Title
NCT00996437	N	P2/P3	completed	Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy (N)

Choroidal Neovascularisation (1)

NCT	Acronym	Phase	Status	Title
NCT01037348	REPAIR	P2	completed	Ranibizumab for the Treatment of Choroidal Neovascularisation (CNV) Secondary to Pathological Myopia (PM): an Individualized Regimen

Sickle Cell Anemia (1)

NCT	Acronym	Phase	Status	Title
NCT00618644	—	N/A	withdrawn	Ranibizumab for Neovascularization in Sickle Cell Retinopathy

Angioid Streaks (1)

NCT	Acronym	Phase	Status	Title
NCT01015495	CNV	P1/P2	withdrawn	Ranibizumab Therapy for Choroidal Neovascularization (CNV) Asociated With Angioid Streaks

Venous Retinal Branch Occlusion (1)

NCT	Acronym	Phase	Status	Title
NCT01011374	—	P1	unknown	Impact of Lucentis on Psychological Morbidity in Patients With Retinal Vein Occlusion

Ocular Histoplasmosis Syndrome (1)

NCT	Acronym	Phase	Status	Title
NCT00955630	IVL for OHS	P1/P2	unknown	Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularization in Ocular Histoplasmosis Syndrome

Myopic Choroidal Neovascularization (1)

NCT	Acronym	Phase	Status	Title
NCT01246089	—	P4	unknown	Ranibizumab for Myopic Neovascularization

Chronic Central Serous Chorioretinopathy (1)

NCT	Acronym	Phase	Status	Title
NCT01325181	—	P1/P2	completed	Ranibizumab Versus Low-fluence Photodynamic Therapy in the Treatment of Chronic Central Serous Chorioretinopathy

Choroidal Neo-Vascular Age-onset Macular Degeneration (1)

NCT	Acronym	Phase	Status	Title
NCT00857259	—	P2	terminated	The Efficacy of Oral Everolimus in Patients With Neovascular Age-related Macular Degeneration

Ophthalmology, Macular Degeneration (1)

NCT	Acronym	Phase	Status	Title
NCT01447043	AURA	N/A	completed	Study to Assess the Effectiveness of Existing Anti vascUlar Endothelial Growth Factor (Anti VEGF) in Patients With Wet Age-related Macular Degeneration (wAMD) (AURA)

Neovascular Glaucoma (1)

NCT	Acronym	Phase	Status	Title
NCT01370135	LucNVG0108	N/A	completed	Study to Evaluate the Effects of Ranibizumab (Lucentis) for Patients With Rubeosis and Neovascular Glaucoma

Retinal Pigment Epithelial Detachment (1)

NCT	Acronym	Phase	Status	Title
NCT00749021	—	P1	completed	Ranibizumab for Treating Submacular Vascularized Pigment Epithelial Detachments

Age-Related Neovascular Macular Degeneration (1)

NCT	Acronym	Phase	Status	Title
NCT00559715	VIBERA	P3	unknown	Prevention of Vision Loss in Patients With Age-Related Macular Degeneration (AMD) by Intravitreal Injection of Bevacizumab and Ranibizumab

Uveitic Cystoid Macular Edema (1)

NCT	Acronym	Phase	Status	Title
NCT00826618	—	P1	completed	Pilot Study of Ranibizumab (Lucentis) for Uveitic Cystoid Macular Edema

Macular Telangiectasia (1)

NCT	Acronym	Phase	Status	Title
NCT00685854	—	P1	completed	Ranibizumab Injections to Treat Macular Telangiectasia Without New Blood Vessel Growth

Neovascularization (1)

NCT	Acronym	Phase	Status	Title
NCT00685503	—	P1	completed	Ranibizumab Injections to Treat Macular Telangiectasia With New Blood Vessel Growth

Neurofibromatosis Type 1 (1)

NCT	Acronym	Phase	Status	Title
NCT00657202	—	Early P1	completed	Ranibizumab for Neurofibromas Associated With Neurofibromatosis 1

Port-Wine Stain (1)

NCT	Acronym	Phase	Status	Title
NCT00667472	—	P1	withdrawn	Combined Pulsed Dye Laser and Topical Ranibizumab for Treatment of Port Wine Stain Birthmarks

Nonarteritic Anterior Ischemic Optic Neuropathy (1)

NCT	Acronym	Phase	Status	Title
NCT00561834	NAION	P1	completed	Ranibizumab Therapy for Non-arteritic Ischemic Optic Neuropathy

Presumed Ocular Histoplasmosis (POHS) (1)

NCT	Acronym	Phase	Status	Title
NCT00546936	—	P2	unknown	Ranibizumab Versus PDT for Presumed Ocular Histoplasmosis

Type 2 Idiopathic Macular Telangiectasia (1)

NCT	Acronym	Phase	Status	Title
NCT00504400	—	P2	completed	Ranibizumab to Treat Type 2 Idiopathic Macular Telangiectasia (RAMA-Trial)

Rubeosis Iridis (1)

NCT	Acronym	Phase	Status	Title
NCT01069341	—	P1	completed	Use of Ranibizumab to Treat Rubeosis in Diabetics Prior to Cataract Surgery

Subfoveal Choroidal Neovascularization (CNV) (1)

NCT	Acronym	Phase	Status	Title
NCT00504959	—	P4	completed	Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration

Coats' Disease (1)

NCT	Acronym	Phase	Status	Title
NCT00470977	FVF4140S	P1/P2	completed	Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy

Conjunctival Neoplasms (1)

NCT	Acronym	Phase	Status	Title
NCT00456495	—	P1	completed	Effect of Ranibizumab on Malignant Conjunctival Neoplasia

Clinically Significant Diabetic Macular Edema (1)

NCT	Acronym	Phase	Status	Title
NCT00440609	—	P1/P2	completed	Study Comparing 0.5mg of Ranibizumab and Higher Doses in the Treatment of Clinically Significant Diabetic Macular Edema

Choroid Neovascularization (1)

NCT	Acronym	Phase	Status	Title
NCT00395057	—	P2	terminated	A Study Using Intravitreal Injections of a Small Interfering RNA in Patients With Age-Related Macular Degeneration

Eales' Disease (1)

NCT	Acronym	Phase	Status	Title
NCT00384449	—	P2/P3	completed	Lucentis (Ranibizumab) for Eales' Disease

Central Serous Chorioretinopathy (1)

NCT	Acronym	Phase	Status	Title
NCT00403325	—	P1	completed	Intravitreal Ranibizumab Treatment of Central Serous Chorioretinopathy

Ischemic Central Retinal Vein Occlusion (1)

NCT	Acronym	Phase	Status	Title
NCT00406471	RAVE	P1	completed	Rubeosis Anti-VEGF (RAVE) Trial for Ischemic Central Retinal Vein Occlusion

Choroidal Neovascularization, Age-related Macular Degeneration (1)

NCT	Acronym	Phase	Status	Title
NCT00379795	—	N/A	completed	An Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects With Choroidal Neovascularization Secondary to AMD or Macular Edema Secondary to RVO

Subfoveal Choroidal Neovascularization(CNV) Secondary to Age-related Macular Degeneration (AMD) (1)

NCT	Acronym	Phase	Status	Title
NCT00284089	—	P1/P2	completed	Safety and Efficacy of Ranibizumab in Japanese Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration

Age-Related Macular Degeneration (ARMD) (1)

NCT	Acronym	Phase	Status	Title
NCT00288561	—	P2	completed	Study of Ranibizumab Administered in Conjunction With Photodynamic Therapy With Verteporfin in Patients With Subfoveal Choroidal Neovascularization and Age-Related Macular Degeneration

Glaucoma, Open-Angle (1)

NCT	Acronym	Phase	Status	Title
NCT00570726	—	P1	completed	Treatment of Failing Blebs With Ranibizumab

Persistent Diabetic Macular Edema (1)

NCT	Acronym	Phase	Status	Title
NCT02127684	—	P2	withdrawn	Frequent Dosing Regimen of Lucentis for Subjects With Persistent Diabetic Macular Edema Despite Standard antiVEGF Dosing

Ranibizumab pivotal trial highlights (Phase 2/3/4)

Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.

Acronym	NCT	Phase	Status	Indication	Enrollment	PubMed
Belvedere	NCT04853251	P4	recruiting	Neovascular Age-related Macular Degeneration	188	—
JQMMT+RA	NCT06234514	P4	completed	Macular Cystoid Edema	111	—
OCTA	NCT04075136	P4	withdrawn	Exudative Age Related Macular Degeneration	0	—
STAMP	NCT03832179	P4	completed	Diabetic Macular Edema	16	PMID 27493795
COVERT	NCT03056092	P4	unknown	Age Related Macular Degeneration	168	—
BEY-RAP	NCT04698850	P4	withdrawn	Wet Macular Degeneration	0	—
REBEL	NCT04991350	P4	terminated	Diabetic Macular Edema	5	PMID 34189816
CyPov	NCT02976194	P4	unknown	Exudative Age-related Macular Degeneration	28	PMID 16490490
RANTA	NCT02806752	P4	unknown	Wet Macular Degeneration	120	—
DME	NCT04087746	P4	completed	Diabetic Macular Edema	400	—
ZIPANGU	NCT02953938	P4	completed	Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO)	59	—
DORO	NCT02665689	P4	terminated	Visual Acuity Reduced Transiently	4	—
SMILE	NCT03042871	P4	completed	Choroidal Neovascularization	54	PMID 12867382
DME	NCT03590444	P4	completed	Diabetic Retinal Edema	50	—
PEARL	NCT02522897	P4	unknown	Central Retinal Vein Occlusion With Macular Edema	60	—
CANARI	NCT02634970	P4	withdrawn	Wet Age-related Macular Degeneration (Wet AMD)	0	—
END-DME	NCT02462304	P4	unknown	Diabetic Macula Edema	60	—
ReCaLL	NCT02059772	P4	unknown	Diabetic Macular Edema	25	PMID 32727496
RVOFV	NCT01795209	P4	terminated	Branch Retinal Vein Occlusion	19	—
RESPONSE	NCT01213667	P4	unknown	Macular Degeneration	110	PMID 25957377
RIVAL	NCT02130024	P4	completed	Age-Related Macular Degeneration	281	PMID 30676617
CAPTAIN	NCT02843490	P4	completed	Neovascular Age-related Macular Degeneration	71	—
TIDE DME	NCT02878681	P4	withdrawn	Visual Impairment Due to Diabetic Macular Edema	0	—
SAFARI	NCT02161575	P4	completed	Neovascular Age-related Macular Degeneration	103	PMID 31383649
TIDE AMD	NCT02257632	P4	completed	Wet Age-Related Macular Degeneration	41	—
DIVERSE	NCT02366468	P4	completed	Diabetic Retinopathy	135	—
SALT	NCT01958918	P4	completed	Neovascular Age-related Macular Degeneration	712	—
ERASER	NCT02107131	P4	completed	Diabetic Macular Edema	40	—
EVEREST II	NCT01846273	P4	completed	Age-related Macular Degeneration	321	PMID 40504425
FLUID	NCT01972789	P4	completed	Subfoveal Choroidal Neovascularization CNV Secondary to Wet Age-related Macular Degeneration AMD	349	PMID 27009515
ARTIS	NCT02810808	P4	unknown	Neovascular Age-related Macular Degeneration	115	PMID 31687203
ORION	NCT01827722	P4	unknown	Macular Edema	45	—
MERLOT	NCT01006538	P4	completed	Macular Degeneration	363	PMID 35217515
TIDE DME	NCT02258009	P4	withdrawn	Visual Impairment Due to Diabetic Macular Edema	0	—
RELIANCE	NCT02577107	P4	completed	Age-related Macular Degeneration	12	—
TWEYES	NCT01986907	P4	completed	Wet Age Related Macular Degeneration	1,049	—
DRAGON	NCT01775124	P4	completed	Neovascular Age-related Macular Degeneration	332	—
WAVE	NCT01710839	P4	completed	Central Retinal, Hemi Retinal & Brach Retinal Vein Occlusions	30	PMID 28318636
RATE	NCT01319188	P4	terminated	Age-related Macular Degeneration	380	—
LUCAS	NCT01127360	P4	completed	Exudative Age-related Macular Degeneration	420	—
CHIC-3	NCT01448018	P4	completed	Central Retinal Vein Occlusion	45	PMID 20953877
BGB/IST	NCT00533520	P4	completed	Macular Degeneration	37	—
RELIGHT	NCT01257815	P4	completed	Diabetic Retinopathy	111	PMID 26150052
RABIMO	NCT01831947	P4	completed	Macular Degeneration	40	—
RaDiVit	NCT01306981	P4	completed	Diabetic Retinopathy	30	—
SEAGUL2	NCT01464723	P4	completed	Age-Related Macular Degeneration	66	PMID 23745581
OPTIMAL	NCT01297569	P4	completed	Diabetic Macular Edema	7	—
LUDIC	NCT01315275	P4	completed	Visual Impairment	394	—
FUSION	NCT01500915	P4	completed	Exudative Age-related Macular Degeneration	17	PMID 22527314
LUCIDATE	NCT01223612	P4	completed	Diabetic Retinopathy	37	—
SALUTE	NCT01148511	P4	completed	Age-related Macular Degeneration	99	—
IVR	NCT02005432	P4	unknown	Proliferative Diabetic Retinopathy	31	PMID 33470281
PDT	NCT00473642	P4	completed	Age-Related Maculopathy	31	—
CLOVER	NCT00680498	P4	completed	Age-Related Macular Degeneration	10	—
PCV	NCT00674323	P4	completed	Polypoidal Choroidal Vasculopathy	61	PMID 25758601
Portal	NCT03683251	P3	recruiting	Neovascular Age-Related Macular Degeneration	1,000	—
HUTONG	NCT05562947	P3	recruiting	Neovascular Age-related Macular Degeneration	68	—
Sightspire	NCT06847542	P3	recruiting	Neovascular Age-related Macular Degeneration	250	—
CoRaLaII	NCT04444492	P3	active not recruiting	Central Retinal Vein Occlusion With Macular Edema	88	—
Pagoda	NCT04108156	P3	active not recruiting	Diabetic Macular Edema	672	PMID 40048197
AMD	NCT06952452	P3	recruiting	Wet Age-related Macular Degeneration	630	—
POYANG	NCT06176352	P3	completed	Choroidal Neovascularization Secondary to Pathologic Myopia	280	—
PAVILION	NCT04503551	P3	completed	Diabetic Retinopathy	174	PMID 40048178
Diagrid	NCT05126966	P3	withdrawn	Neovascular Age-Related Macular Degeneration	0	—
IVT	NCT05480293	P3	unknown	Wet Age-related Macular Degeneration	446	—
ShORe	NCT04757610	P3	terminated	Neovascular Age-related Macular Degeneration	986	—
nAMD	NCT05461339	P3	active not recruiting	Neovascular Age-related Macular Degeneration	488	—
AMD	NCT06190093	P3	completed	Neovascular Age-related Macular Degeneration	400	—
STAR	NCT02243878	P3	completed	Neovascular (Wet) Age-related Macular Degeneration (AMD)	411	PMID 27881184
RainbowExt	NCT02640664	P3	completed	Retinopathy of Prematurity (ROP)	180	PMID 34391532
MERIT	NCT02623426	P3	completed	Uveitis	194	PMID 37318415
aiRTo-PDR	NCT02447185	P3	unknown	Proliferative Diabetic Retinopathy	200	PMID 17804919
XPLORE	NCT03805100	P3	completed	Macular Degeneration	582	—
AMD	NCT03834753	P3	completed	Age-related Macular Degeneration	228	—
Archway	NCT03677934	P3	completed	Neovascular Age-Related Macular Degeneration	415	PMID 39447871
AMD	NCT03844074	P3	completed	Age-related Macular Degeneration	61	—
DR	NCT03452657	P3	unknown	Diabetic Retinopathy	118	—
AMD	NCT03150589	P3	completed	Age-Related Macular Degeneration	705	PMID 33211076
CEDAR	NCT02462928	P3	completed	Macular Degeneration	939	—
Protocol T	NCT01627249	P3	completed	Diabetic Macular Edema	660	PMID 25692915
COLUMBUS-AMD	NCT02611778	P3	completed	Age-related Macular Degeneration (AMD)	712	—
Protocol S	NCT01489189	P3	completed	Proliferative Diabetic Retinopathy	305	PMID 26565927
MAKO	NCT02727881	P3	unknown	Age-related Macular Degeneration	230	—
RAINBOW	NCT02375971	P3	completed	Retinopathy of Prematurity	224	PMID 31522845
T-REX	NCT01748292	P3	completed	Macular Degeneration	60	PMID 28779006
REFINE	NCT02259088	P3	completed	Diabetic Macular Edema	384	—
CONTROL	NCT03495765	P3	completed	Diabetic Macular Oedema	160	—
E10030	NCT01940900	P3	terminated	Age-Related Macular Degeneration	627	—
E10030	NCT01944839	P3	terminated	Age-Related Macular Degeneration	619	PMID 30957581
Brilliance	NCT01922102	P3	completed	Visual Impairment Due to Choroidal Neovascularization (CNV) Secondary to Pathologic Myopia (PM)	457	—
OLIMPIC	NCT02034006	P3	completed	Choroidal Neovascularization Secondary to Pathologic Myopia	200	PMID 30680452
PFS	NCT02698566	P3	completed	Macular Edema	35	PMID 29853609
Blossom	NCT01976338	P3	completed	Macular Edema Secondary to Branch Retinal Vein Occlusion	283	PMID 31902472
Camellia	NCT01976312	P3	completed	Central Retinal Vein Occlusion	252	—
ECLIPSE	NCT01908816	P3	completed	Choroidal Neovascularization	270	—
TREND	NCT01948830	P3	completed	Age-related Macular Degeneration	650	PMID 31563866
OCTAVE	NCT01780935	P3	completed	Neovascular Age-related Macular Degeneration	671	PMID 31918685
BRIGHTER	NCT01599650	P3	completed	Branch Retinal Vein Occlusion	455	PMID 27039022
CONSTELLATION	NCT02032173	P3	terminated	Macular Edema	31	—
CRYSTAL	NCT01535261	P3	completed	Macular Edema	357	PMID 31047340
LRT for DME	NCT00444600	P3	completed	Diabetic Retinopathy	691	PMID 25439614
COMRADE-C	NCT01396083	P3	completed	Visual Impairment	243	—
GALATIR	NCT02036723	P3	withdrawn	Wet Age-related Macular Degeneration	0	—
COMRADE-B	NCT01396057	P3	completed	Visual Impairment	244	PMID 32633861
RETAIN	NCT01171976	P3	completed	Diabetic Macular Edema	373	PMID 26453639
RESPOND	NCT01135914	P3	completed	Diabetic Macular Edema	241	—
RETAIN	NCT01198327	P3	completed	Retinal Vein Occlusion	66	PMID 20398941
FVF4193s	NCT01255774	P3	unknown	Age Related Macular Degeneration	20	—
RISE	NCT00473330	P3	completed	Diabetes Mellitus	377	PMID 31047503
RIDE	NCT00473382	P3	completed	Diabetes Mellitus	382	PMID 30419298
HARBOR	NCT00891735	P3	completed	Age-related Macular Degeneration	1,097	PMID 39287532
CABERNET	NCT00454389	P3	unknown	Macular Degeneration	494	—
CARBON	NCT00557791	P3	withdrawn	Age Related Macular Degeneration	0	—
RVO in Japan	NCT01377597	P3	completed	Retinal Vein Occlusion	47	PMID 27654837
AxL-2009	NCT01014468	P3	unknown	Age Related Macular Degeneration	500	—
RESTORE	NCT00687804	P3	completed	Diabetic Macular Edema	345	PMID 24491642
REVEAL	NCT00989989	P3	completed	Diabetic Macular Edema	396	—
BRVO	NCT01189526	P3	unknown	Branch Retinal Vein Occlusion	60	—
VIEW 2	NCT00637377	P3	completed	Macular Degeneration	1,240	PMID 24084500
RELATION	NCT01131585	P3	terminated	Visual Impairment Due to Diabetic Macular Edema	128	—
VIEW1	NCT00509795	P3	completed	Macular Degeneration	1,217	PMID 25439429
VIBERA	NCT00559715	P3	unknown	Age-Related Neovascular Macular Degeneration	366	—
LRTforDME+PRP	NCT00445003	P3	completed	Proliferative Diabetic Retinopathy	333	PMID 21459214
AMD	NCT00599222	P3	completed	Neovascular Age-related Macular Degeneration	100	PMID 22241923
RVO	NCT00942864	P3	completed	Macular Edema	40	—
CRUISE	NCT00485836	P3	completed	Macular Edema	392	—
BRAVO	NCT00486018	P3	completed	Macular Edema	397	PMID 23699977
COBALT	NCT00499590	P3	terminated	Macular Degeneration	338	—
EXTEND II	NCT00826371	P3	completed	Age Related Macular Degeneration	114	PMID 25012926
CNV	NCT00470678	P3	completed	Choroidal Neovascularization	95	PMID 22382503
PDR	NCT00516464	P3	unknown	Proliferative Diabetic Retinopathy	40	PMID 37260074
MANTA	NCT00710229	P3	unknown	Age Related Macular Degeneration	320	PMID 23292928
EXCITE	NCT00275821	P3	completed	Age Related Macular Degeneration	353	—
CNV	NCT00251459	P3	completed	Choroidal Neovascularization	5,000	PMID 19643495
AMD	NCT00090623	P3	completed	Macular Degeneration	180	PMID 18222192
AMD	NCT00095433	P3	completed	Macular Degeneration	100	—
AAVIATE	NCT04514653	P2	active not recruiting	Neovascular Age-Related Macular Degeneration (nAMD)	146	—
RO7200220	NCT05151731	P2	completed	Diabetic Macular Edema	394	—
RO7200220	NCT05151744	P2	completed	Diabetic Macular Edema	187	—
ZEBRA	NCT03423823	P2	completed	Wet Macular Degeneration	62	—
DME	NCT03499223	P2	completed	Diabetes Mellitus	70	—
RRR	NCT02222610	P2	completed	Radiation Retinopathy	40	PMID 34463842
LADDER	NCT02510794	P2	completed	Macular Degeneration	225	PMID 35248647
STAIRWAY	NCT03038880	P2	completed	Neovascularization, Choroidal	76	PMID 32729897
BOULEVARD	NCT02699450	P2	completed	Diabetic Macular Edema	229	PMID 30905643
PRIDE	NCT01594281	P2	completed	Proliferative Diabetic Retinopathy (PDR)	107	—
AVENUE	NCT02484690	P2	completed	Choroidal Neovascularization	273	PMID 37422192
ARK	NCT02067013	P2	unknown	Proliferative Diabetic Retinopathy	45	—
CARE-ROP	NCT02134457	P2	completed	Retinopathy of Prematurity (ROP)	19	PMID 29309486
RabOCT	NCT01968239	P2	completed	Branch Retinal Vein Occlusion	27	—
READ-4	NCT02511067	P2	withdrawn	Diabetic Macular Edema	0	PMID 23975003
EMERGE	NCT02358889	P2	completed	Choroidal Neovascularization	88	—
VIDI	NCT02302079	P2	completed	Diabetes Mellitus	96	PMID 31388454
RIP	NCT01914159	P2	completed	Age Related Macular Degeneration	24	—
DREAM	NCT02222207	P2	terminated	Macular Degeneration	52	—
TIME-2	NCT02050828	P2	completed	Diabetic Macular Edema (DME)	144	—
STAR	NCT01243086	P2	completed	Wet Macular Degeneration	10	PMID 18054638
iDEAL	NCT01565148	P2	terminated	Diabetic Macular Edema	185	—
MINIMA-2	NCT01112085	P2	completed	Diabetic Macular Edema	72	—
Antibody	NCT00931489	P2	completed	Age Related Macular Degeneration	131	—
Revolution	NCT01247220	P2	completed	Macular Edema	12	—
AMD	NCT01397409	P2	completed	Age-related Macular Degeneration	271	PMID 30412448
PRP	NCT01280929	P2	completed	High Risk Proliferative Diabetic Retinopathy	54	PMID 26630400
VITARM	NCT00931125	P2	unknown	Diabetic Retinopathy	70	—
MATISSE	NCT01445899	P2	completed	Choroidal Neovascularization	258	—
HiPED	NCT01189019	P2	terminated	Wet Macular Degeneration	40	—
READ 3	NCT01077401	P2	completed	Diabetic Macular Edema	152	—
PADDLE	NCT00831350	P2	completed	Retinal Vein Occlusion	32	—
HD-LIPT	NCT01205035	P2	completed	Retinal Diseases	6	—
IBERA-DME	NCT01487629	P2	unknown	Diabetic Retinopathy	53	PMID 23795985
REPAIR	NCT01037348	P2	completed	Choroidal Neovascularisation	65	PMID 24001532
RACE	NCT01157065	P2	completed	Exudative Age-Related Macular Degeneration	99	—
STAR	NCT01249937	P2	unknown	Wet Macular Degeneration	30	—
BRAVO	NCT01123564	P2	unknown	Retinal Vein Occlusion	40	—
SURFING	NCT00846625	P2	withdrawn	Macular Edema	0	—
RaScaL	NCT00815360	P2	completed	Diabetic Macular Edema	22	—
READ-2	NCT00407381	P2	completed	Diabetic Macular Edema	126	PMID 23544200
MONET	NCT00713518	P2	completed	Age Related Macular Degeneration	152	—
AMD	NCT00992563	P2	completed	Age Related Macular Degeneration	35	—
IRaHi	NCT01102946	P2	completed	Diabetic Retinopathy	40	—
RADICAL	NCT00492284	P2	completed	Choroidal Neovascularization	162	—
AMD	NCT00775411	P2	completed	Choroidal Neovascularization	44	—
CNV	NCT00510965	P2	completed	Choroidal Neovascularization	10	PMID 21704964
EMERALD	NCT00766337	P2	terminated	Age-Related Macular Degeneration	62	—
RANITRA	NCT01201161	P2	completed	Diabetic Retinopathy	19	—
RAP	NCT00527475	P2	completed	Macular Degeneration	60	—
PDEX	NCT00390208	P2	completed	Age Related Macular Degeneration	60	PMID 11381074
Luvi	NCT00574093	P2	completed	Neovascular Age Related Macular Degeneration	15	—
AMD	NCT00511706	P2	completed	Choroidal Neovascularization	243	PMID 26088793
RESOLVE	NCT00284050	P2	completed	Diabetic Macular Edema	151	PMID 20980427
IECOMB	NCT00413829	P2	completed	Age Related Macular Degeneration	20	PMID 19878113

Terminated and withdrawn Ranibizumab trials (55)

Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.

NCT05126966withdrawnA Study Of The Effectiveness And Safety Of A 36-Week Refill Regimen For The Port Delivery System With Ranibizumab Vs Aflibercept Treat & Extend In Subjects With Neovascular Age-Related Macular Degeneration
NCT04757610terminatedOPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD)
NCT04075136withdrawnOptical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy
NCT03784443withdrawnCombined Ranibizumab and Iluvien for Diabetic Macular Oedema
NCT02207712terminatedNoctura400 Treatment for Diabetic Retinopathy (CANDLE)
NCT04698850withdrawnBrolucizumab vs. Aflibercept for Retinal Angiomatous Proliferation
NCT04991350terminatedEffect of Ranibizumab Versus Bevacizumab on the Macular Perfusion in Diabetic Macular Edema
NCT02665689terminatedInfluence of Diabetes Control on Treatment of Diabetic Macular Edema With Ranibizumab
NCT02634970withdrawnCANadian Study in Patients With Wet AMD, Evaluating the Efficacy and Safety of Switching From Intravitreal Aflibercept to RanIbizumab
NCT01795209terminatedRanibizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion in Patients With Fair Vision
NCT02878681withdrawn24 Week Study to Compare Systemic VEGF-levels of Ranibizumab and Aflibercept in DME.
NCT02281292withdrawnA Study of the Safety and Tolerability of Intravitreal LKA651 in Patients With Diabetic Macular Edema
NCT02387957terminatedA 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)
NCT01940900terminatedA Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy
NCT01944839terminatedA Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy
NCT02258009withdrawnSystemic VEGF Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema
NCT02511067withdrawnRanibizumab for Edema of the mAcula in Diabetes: Protocol 4 With Tocilizumab: The READ-4 Study
NCT02398500terminatedSafety Tolerability and Efficacy of Intravitreal LMG324 in the Treatment of Neovascular Age-Related Macular Degeneration
NCT02511613withdrawnEffect of Squalamine Lactate Ophthalmic Solution, 0.2% in Subjects With Neovascular Age-Related Macular Degeneration
NCT02127684withdrawnFrequent Dosing Regimen of Lucentis for Subjects With Persistent Diabetic Macular Edema Despite Standard antiVEGF Dosing
NCT01994291terminatedA Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema
NCT02055911withdrawnRetinal Ganglion Cell Function After Intravitreous Ranibizumab in Patients With Diabetic Macular Edema
NCT02222207terminatedRegorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
NCT01319188terminatedRanibizumab and the Risk of Arterial Thromboembolic Events
NCT02032173terminatedEfficacy and Safety of Lucentis® Use in Patients With Diabetic Macular Edema Evaluating a Spaced Out Follow-up After Intensive Treatment Phase
NCT01402544terminatedClinical Assessment Of Age-related Macular Degeneration Patients After Early Diagnosis and Treatment With Ranibizumab
NCT01565148terminatedA Randomized, Multi-center, Phase II Study of the Safety, Tolerability and Bioactivity of Repeated Intravitreal Injections of iCo-007 as Monotherapy or in Combination With Ranibizumab or Laser Photocoagulation in the Treatment of Diabetic Macular Edema (the iDEAL Study)
NCT02036723withdrawnSafety and Efficacy Study of BCD-021 Compared to Lucentis® in Patients With Neovascular Wet Age-related Macular Degeneration
NCT00667472withdrawnCombined Pulsed Dye Laser and Topical Ranibizumab for Treatment of Port Wine Stain Birthmarks
NCT01189019terminatedHiPED - High Dose Lucentis for Persistent Pigment Epithelial Detachments in Age-related Macular Degeneration
NCT01025232terminatedA Study of Intravitreal Injections of 2.0mg Ranibizumab in Subjects With Chronic Fluid On OCT Post Multiple Injections With Ranibizumab (Super-dose Anti-VEgf SAVE Trial)
NCT01225146terminatedStudy of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2)
NCT01253694withdrawnRanibizumab as a Rescue Therapy for Diabetic Macular Edema
NCT00557791withdrawnSafety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD (CARBON)
NCT00726973withdrawnPilot Study Reduced Fluence PDT /Visudyne With Ranibizumab vs Ranibizumab Monotherapy for Exudative Age-related Macular Degeneration (AMD)
NCT01406639withdrawnRanibizumab for the Management of Recurrent Nosebleeds in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)
NCT00668785terminatedIntravitreal Ranibizumab to Treat Macular Edema After Panretinal Photocoagulation (Phase II)
NCT00709657terminatedThe Effect of a Single Intravitreal Anti-VEGF Therapy on Optic Nerve Head Perfusion
NCT00846625withdrawnStudy of Uveitic Macular Edema Treated With Ranibizumab or Steroids
NCT01131585terminatedSafety and Efficacy of Ranibizumab in Diabetic Macular Edema
NCT00618644withdrawnRanibizumab for Neovascularization in Sickle Cell Retinopathy
NCT01122511terminatedSafety and Efficacy of Dexamethasone as Adjunctive Therapy to Ranibizumab in Subjects With Choroidal Neovascularization and Age-Related Macular Degeneration
NCT01015495withdrawnRanibizumab Therapy for Choroidal Neovascularization (CNV) Asociated With Angioid Streaks
NCT00644280terminatedRanibizumab in Preventing Failure of Ahmed Valve Glaucoma Surgery
NCT00676559withdrawnCombined aPproach to Treatment Using Ranibizumab and Efalizumab for Diabetic Macular Edema Study: The CAPTURE DME Study
NCT00766337terminatedPhase 2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Combination With Lucentis® in Patients With Age-Related Macular Degeneration
NCT00433017terminatedVerteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)
NCT00499590terminatedSafety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD
NCT00727038withdrawnLucentis for New Onset Neovascular Glaucoma
NCT00857259terminatedThe Efficacy of Oral Everolimus in Patients With Neovascular Age-related Macular Degeneration
NCT00395057terminatedA Study Using Intravitreal Injections of a Small Interfering RNA in Patients With Age-Related Macular Degeneration
NCT00423189terminatedLucentis Utilizing Visudyne (LUV Trial) Combination Therapy in the Treatment of Age-Related Macular Degeneration
NCT00726466withdrawnStudy of Efalizumab Combined With Intravitreal Ranibizumab in the Treatment of Age-Related Macular Degeneration
NCT00403156withdrawnImatinib Mesylate Combined With Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
NCT00930189withdrawnComparative Study With Photodynamic Therapy And Triamcinolone Versus Photodynamic Therapy, Triamcinolone And Ranibizumab In Patients With Subfoveal Choroidal Neovascularization

All Ranibizumab trials (480)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

NCT ID	Acronym	Title	Phase	Status	Enrollment	Sponsor	Started
NCT07007065		Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)	P3	recruiting	561	AbbVie	Nov 2025
NCT03683251	Portal	Extension Study for the Port Delivery System With Ranibizumab (Portal)	P3	recruiting	1,000	Hoffmann-La Roche	Sep 2018
NCT05562947	HUTONG	A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD)	P3	recruiting	68	Hoffmann-La Roche	Jun 2024
NCT07249216	M-VIVA	Identification of Molecular Signals in Vitreous Humor Associated With Suboptimal Response to Vascular Endothelial Growth Factor (VEGF) Inhibition in Neovascular Age-related Macular Degeneration (nAMD) Within a Clinical Trial Setting	N/A	recruiting	117	Singapore National Eye Centre	Jul 2025
NCT06847542	Sightspire	A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD	P3	recruiting	250	Hoffmann-La Roche	Nov 2025
NCT06957080	BAROLO	A Study of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME	P2/P3	active not recruiting	1,054	EyeBiotech Ltd.	Apr 2025
NCT06571045	BRUNELLO	A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME	P2/P3	active not recruiting	984	EyeBiotech Ltd.	Aug 2024
NCT05476926	VOYAGER	A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products	—	active not recruiting	6,000	Hoffmann-La Roche	Nov 2022
NCT04704921	ATMOSPHERE	Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD	P2/P3	active not recruiting	671	AbbVie	Dec 2020
NCT04444492	CoRaLaII	Combination of Ranibizumab and Targeted Laser Photocoagulation	P3	active not recruiting	88	University of Giessen	Aug 2020
NCT04853251	Belvedere	A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)	P4	recruiting	188	Genentech, Inc.	Dec 2021
NCT04108156	Pagoda	A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME	P3	active not recruiting	672	Hoffmann-La Roche	Sep 2019
NCT03161652		Effect of Levosulpiride on Retinal Alterations in Patients With Diabetic Retinopathy and Diabetic Macular Edema	P2	recruiting	120	Carmen Clapp	May 2017
NCT07520045		Biomarkers in Diabetic Retinopathy Treated With Faricimab vs Biosimilar Ranibizumab	N/A	recruiting	100	Osijek University Hospital	Mar 2026
NCT04514653	AAVIATE	RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)	P2	active not recruiting	146	AbbVie	Aug 2020
NCT04657289		A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)	P3	active not recruiting	451	Hoffmann-La Roche	Jul 2021
NCT04567303	BURGUNDY	Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration	P1/P2	active not recruiting	177	Hoffmann-La Roche	Oct 2020
NCT06952452	AMD	Pharmacogenomics of antiVEGF in Patients With Age-Associated Macular Degeneration (AMD)	P3	recruiting	630	Parc de Salut Mar	Nov 2022
NCT06176352	POYANG	A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia	P3	completed	280	Hoffmann-La Roche	Mar 2024
NCT04503551	PAVILION	A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm	P3	completed	174	Hoffmann-La Roche	Aug 2020
NCT05126966	Diagrid	A Study Of The Effectiveness And Safety Of A 36-Week Refill Regimen For The Port Delivery System With Ranibizumab Vs Aflibercept Treat & Extend In Subjects With Neovascular Age-Related Macular Degeneration	P3	withdrawn	0	Hoffmann-La Roche	Dec 2023
NCT06305416		A Efficacy and Safety Study of Ranibizumab 10mg/ml Injection (Incepta) in Patients With Diabetic Macular Edema	P3	recruiting	70	Incepta Pharmaceuticals Ltd	Mar 2024
NCT04140448	UWFA-RVO-ME	Ultra-wide-field Fluorescein Angiography in Patients With Macular Edema Secondary to Retinal Vein Occlusion	—	unknown	60	Renmin Hospital of Wuhan University	Oct 2023
NCT05480293	IVT	This Study Will Compare the Efficacy and Safety of SCT510A Administered by Intravitreal Injection (IVT) With Ranibizumab in Patients With wAMD	P3	unknown	446	Sinocelltech Ltd.	Feb 2023
NCT06234514	JQMMT+RA	Manage Macular Cystoid Edema With Retinal Vein Obstruction Using Traditional Chinese Medicine and Ranibizumab	P4	completed	111	Dongyang People's Hospital	Jan 2023
NCT05151731	RO7200220	A Study to Investigate Vamikibart (RO7200220) in Diabetic Macular Edema	P2	completed	394	Hoffmann-La Roche	Dec 2021
NCT04757610	ShORe	OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD)	P3	terminated	986	Opthea Limited	Mar 2021
NCT05461339	nAMD	TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration	P3	active not recruiting	488	BioDlink Biopharm Co., Ltd.	Jun 2022
NCT04075136	OCTA	Optical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy	P4	withdrawn	0	Wake Forest University Health Sciences	Mar 2023
NCT04740671		A Phase 3 Study to Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD	P3	completed	410	Shanghai Henlius Biotech	Jul 2021
NCT02321267		Cohort Study of the Clinical Course of Macular Diseases in Kagawa	P4	unknown	1,000	Kagawa University	Dec 2014
NCT05248334		A Prospective Study of Ranibizumab in the Treatment of Postoperative Recurrent Vitreous Haemorrhage of Diabetic Retinopathy	P1	unknown	120	Tianjin Medical University Eye Hospital	Apr 2022
NCT06190093	AMD	A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)	P3	completed	400	Outlook Therapeutics, Inc.	Jan 2024
NCT05861466		Comparative Study Between IVI of Ranibizumab with and Without Prior ACP in Patients with DME Using OCT-A	P4	completed	102	Ain Shams University	Jan 2023
NCT05151744	RO7200220	A Study to Investigate Vamikibart (RO7200220) in Combination With Ranibizumab in Diabetic Macular Edema	P2	completed	187	Hoffmann-La Roche	Dec 2021
NCT05520177		A Phase III Study for 601 Versus Ranibizumab in Patients With Vision Loss	P3	completed	351	Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.	Dec 2022
NCT07389577		A Study to Compare JL14002 to Lucentis® in Subjects With Wet Age-related Macular Degeneration (wAMD)	P3	completed	443	Jecho Biopharmaceuticals Co., Ltd.	Mar 2022
NCT06205979		Relationship Between Dyslipidemia and The Response of Diabetic Macular Edema to Intravitreal Injection of Anti Vascular Endothelial Growth Factor Agents	Early P1	unknown	50	Sohag University	Dec 2023
NCT05138029		Study on Precision Treatment of Diabetic Retinopathy Macular Edema Guided by Real-time OCT During Operation	P3	unknown	60	Affiliated Hospital of Nantong University	Nov 2021
NCT04690556		Study to Compare Efficacy, Safety, and Immunogenicity of LUBT010 (Proposed Ranibizumab Biosimilar) and Lucentis® in Patients With Neovascular AMD	P3	completed	600	Lupin Ltd.	Sep 2020
NCT02243878	STAR	Stereotactic Radiotherapy for Wet AMD (STAR)	P3	completed	411	King's College Hospital NHS Trust	Dec 2014
NCT02081339		Cohort Study of the Clinical Course of Macular Diseases in Japanese	—	unknown	1,000	Kyoto University, Graduate School of Medicine	Mar 2014
NCT03832179	STAMP	Steroid vs. Anti-vascular Endothelial Growth Factor for Diabetic Macular Edema Prior to Phacoemulsification	P4	completed	16	Bay Area Retina Associates	Nov 2018
NCT03056092	COVERT	Cytokine and Visual Outcome Variations in Eyes Receiving Ranibizumab	P4	unknown	168	Unity Health Toronto	Feb 2017
NCT06771271	DOVETAIL	A Study to Investigate RO7200220 as Monotherapy and in Combination With Ranibizumab in Participants With Diabetic and Uveitic Macular Edema	P1	completed	85	Hoffmann-La Roche	Jul 2019
NCT06179030		Systemic and Local Inflammatory Biomarkers in the Treatment of Refractory Diabetic Macular Edema	—	completed	80	Saglik Bilimleri Universitesi	May 2022
NCT03784443	CASSIE	Combined Ranibizumab and Iluvien for Diabetic Macular Oedema	P2/P3	withdrawn	0	Imperial College London	Sep 2019
NCT02207712	CANDLE	Noctura400 Treatment for Diabetic Retinopathy (CANDLE)	N/A	terminated	252	PolyPhotonix Medical	Nov 2014
NCT04922151		601 Versus Ranibizumab in Patients With Pathological Myopic Choroidal Neovascularization (pmCNV)	P2	unknown	60	Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.	Jun 2021
NCT04698850	BEY-RAP	Brolucizumab vs. Aflibercept for Retinal Angiomatous Proliferation	P4	withdrawn	0	Faculty Hospital Kralovske Vinohrady	Jan 2021
NCT04662944	RAZORBILL	A Non-interventional Study to Assess the Influence of Automated Optical Coherence Tomography Image Enrichment With Segmentation Information on Disease Activity Assessment in Patients Treated With Licensed Anti- VEGF Injections	—	completed	494	Novartis Pharmaceuticals	Feb 2021
NCT03999125		Anti-VEGF Therapy Versus Dexamethasone Implant for DME	P4	unknown	150	Sudhalkar Eye Hospital	Jun 2019
NCT05222633		Anti-VEGF in Real-world	—	unknown	1,000	Wenbin Wei	Jan 2022
NCT05386160		Phacoemulsification Combined With Intravitreal Injection of Ranibizumab Prevent Postoperative Capillary Non-perfusion Zone Progress in Non-proliferative Diabetic Retinopathy	P4	unknown	96	Ruijin Hospital	Jul 2022
NCT05701124		Intravitreal Ranibizumab Injection for Aggressive Versus Type 1 Prethreshold Retinopathy of Prematurity	P3	completed	30	Zagazig University	Nov 2020
NCT04991350	REBEL	Effect of Ranibizumab Versus Bevacizumab on the Macular Perfusion in Diabetic Macular Edema	P4	terminated	5	Cairo University	Nov 2021
NCT05033106		Ranibizumab Vs Bevacizumab for Type 1 Retinopathy of Prematurity	P3	unknown	36	Zagazig University	Sep 2020
NCT04062370		Ranibizumab Treatment for Macular Edema Secondary to Retinal Vein Occlusion	P4	unknown	100	Sun Yat-sen University	Oct 2019
NCT05080803		Diabetic Macular Edema: Relevance of Staging Progression on Therapeutic Outcome	—	completed	608	European School of Advanced Studies in Ophthalmology	Jun 2021
NCT03709745		Eylea and Lucentis for Macular Edema in Branch Retinal Vein Occlusion	P4	completed	110	St. Erik Eye Hospital	Oct 2018
NCT04464694		Pre-vitrectomy Intravitreal Ranibizumab for Patients With Proliferative Diabetic Retinopathy Combined With Diabetic Macular Edema	P4	unknown	142	Xinhua Hospital, Shanghai Jiao Tong University School of Medicine	Sep 2020
NCT05282420		Ranibizumab Versus Aflibercept for CRVO in Young Patients.	P4	unknown	40	South Valley University	Feb 2021
NCT02640664	RainbowExt	Rainbow Extension Study	P3	completed	180	Novartis Pharmaceuticals	Jun 2016
NCT02623426	MERIT	Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial	P3	completed	194	JHSPH Center for Clinical Trials	Mar 2017
NCT02447185	aiRTo-PDR	25-G Vitrectomy With Ranibizumab or Triamcinolone Acetonide on PDR in China-Randomized Clinical Trial	P3	unknown	200	JUNYAN ZHANG	Jun 2015
NCT04460001	CRVO	Injection of Ranibizumab Versus Combination of Ranibizumab and Triamcinolone Acetate for (CRVO)	P2/P3	unknown	100	Assiut University	May 2019
NCT03805100	XPLORE	Comparing the Efficacy and Safety of Biosimilar Candidate Xlucane Versus Lucentis® in Patients With nAMD	P3	completed	582	Xbrane Biopharma AB	Apr 2019
NCT03690947		Combination of Intravitreal Ranibizumab With or Without Micropulse Laser for the Treatment of DME	P4	completed	72	Beijing Hospital	Oct 2018
NCT04601675	DME	Diabetic Macular Edema (DME) Treatment With Ranibizumab and Dexamethasone or Ranibizumab Only.	N/A	unknown	100	He Eye Hospital	Oct 2020
NCT03834753	AMD	A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)	P3	completed	228	Outlook Therapeutics, Inc.	Jun 2019
NCT03725501		Evaluation of the Safety and Efficacy of ALS-L1023 Administered in Combination With Ranibizumab in Patients With Wet-AMD	P2	completed	126	AngioLab, Inc.	Dec 2018
NCT03677934	Archway	A Phase III Study to Evaluate the Port Delivery System With Ranibizumab Compared With Monthly Ranibizumab Injections in Participants With Wet Age-Related Macular Degeneration	P3	completed	415	Hoffmann-La Roche	Sep 2018
NCT02174211	VITCLEAR	A Pharmacokinetic Study: Ranibizumab, Aflibercept and the Effect of Vitrectomy.	N/A	completed	59	King's College Hospital NHS Trust	Jun 2014
NCT04714242		OCTA and Polypoidal Choroidal Vasculopathy	—	completed	60	Federico II University	Jan 2019
NCT03844074	AMD	A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)	P3	completed	61	Outlook Therapeutics, Inc.	Oct 2018
NCT03759860		Laser (Selective Retina Therapy) and Drug Combined Intervention in Clinically Significant Diabetic Macular Edema	P4	unknown	12	CynosureLutronic	Jan 2018
NCT02140151	PREVENT	Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration	P1/P2	completed	108	Southern California Desert Retina Consultants, MC	Sep 2014
NCT03452657	DR	Multicenter Clinical Study of Anti-VEGF Treatment on High Risk Diabetic Retinopathy (DR)	P3	unknown	118	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	Apr 2018
NCT03423823	ZEBRA	Ziv-aflibercept Efficacy in Better Regulating AMD	P2	completed	62	Kapil Kapoor	Jul 2017
NCT04878835		Effects of Ranibizumab in Primary Pterygium Surgery	P1	completed	52	Universiti Sains Malaysia	May 2018
NCT04539106		Intravitreal Ranibizumab in Recurrent ROP	—	completed	115	Ameera Gamal Abdelhameed	Jun 2019
NCT03944070		Management of Patients With Neovascular Age-related Macular Degeneration Undergoing Cataract Surgery	N/A	unknown	16	Ophthalmica Eye Institute	Jan 2018
NCT02976194	CyPov	Intraocular Cytokine in Recurrence of Polypoidal Choroidal Vasculopathy	P4	unknown	28	Pusan National University Hospital	Nov 2016
NCT03973138	IVRDME	Visual Outcomes and the Predictive Factors in Chinese Patients With Diabetic Macular Edema Treated With Ranibizumab	P1/P2	unknown	100	Sun Yat-sen University	Jan 2015
NCT02806752	RANTA	Intravitreal Ranibizumab and TA Combination Therapy vs. Ranibizumab Monotherapy in Polypoidal Choroidal Vasculopathy	P4	unknown	120	Aier School of Ophthalmology, Central South University	Jan 2017
NCT04310631		Evaluation of Retinal and Vascular Features in Coats Disease After Intravitreal Injections of Ranibizumab	—	completed	5	Federico II University	Jan 2016
NCT01835067	TAPAS	Intravitreal tPA and C3F8 for the Treatment of Submacular Haemorrhage as a Complication of Neovascular AMD	P2/P3	completed	55	King's College Hospital NHS Trust	Sep 2014
NCT03150589	AMD	A Study to Compare SB11 (Proposed Ranibizumab Biosimilar) to Lucentis in Subjects With Neovascular Age-related Macular Degeneration (AMD)	P3	completed	705	Samsung Bioepis Co., Ltd.	Mar 2018
NCT04377295		Evaluation of Retinal and Vascular Features in Radiation Maculopathy After Intravitreal Injections of Ranibizumab	—	completed	40	Federico II University	Oct 2012
NCT01968616		Ranibizumab Treatment for Retinal Vein Occlusion	N/A	unknown	100	Kyoto University, Graduate School of Medicine	Sep 2013
NCT03763227		Intravitreal Ranibizumab (Lucentis®) in the Treatment of Non-leaking Macular Cysts in Retinal Dystrophy	P2	completed	13	Sultan Qaboos University	Jul 2015
NCT03499223	DME	A Study to Evaluate THR-317 and Ranibizumab Combination Treatment for Diabetic Macular Oedema (DME)	P2	completed	70	Oxurion	Apr 2018
NCT02859441		A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab	P1/P2	completed	3	National Eye Institute (NEI)	Jan 2017
NCT04087746	DME	Comparison of Aflibercept Versus Ranibizumab in Management of Diabetic Macular Edema (DME)	P4	completed	400	Minia University	Jan 2017
NCT02462928	CEDAR	A Safety and Efficacy Study of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration	P3	completed	939	Allergan	Jun 2015
NCT02462486		Safety and Efficacy of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration	P3	completed	949	Allergan	Jun 2015
NCT03071055		Efficacy of Biweekly Ranibizumab (0.5 mg) for Exudative Macular Degeneration Retinal Edema Refractory to Anti-VEGF	P2	completed	20	Southeast Clinical Research Associates, LLC	Oct 2017
NCT03345082		A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD	P2	completed	366	Opthea Limited	Nov 2017
NCT04089605		Ranibizumab vs Dexamethasone Implant in Vitrectomized Eyes With Diabetic Macular Edema	P4	completed	48	Far Eastern Memorial Hospital	Jun 2017
NCT01627249	Protocol T	Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema	P3	completed	660	Jaeb Center for Health Research	Aug 2012
NCT02222610	RRR	Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation to Treat Radiation Retinopathy.	P2	completed	40	Greater Houston Retina Research	Sep 2014
NCT02321839		Evaluation of the Usefulness of a Treat and Extend Regimen Using Ranibizumab for Neovascular AMD.	P4	completed	78	Nagoya City University	Jan 2014
NCT02478515		Evaluation of the Usefulness of a PRN Regimen Using Ranibizumab for Macular Edema Due to Branch Retinal Vein Occlusion	P4	completed	27	Nagoya City University	Jan 2014
NCT02510794	LADDER	Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration	P2	completed	225	Genentech, Inc.	Sep 2015
NCT04387604	DEVITRA	Effect of the Vitreous in Response to Intravitreal Injections of Ranibizumab for the Treatment of Diabetic Macular Edema	—	completed	50	Centro Hospitalar do Porto	Aug 2017
NCT02864472		Comparison of PDT Combination With Ranibizumab vs. Ranibizumab Monotherapy in Persistent PCV With Initial Loading Dose	P4	unknown	40	Seoul National University Hospital	Sep 2016
NCT03054766		Combination of Intravitreal Ranibizumab With or Without Macular Laser Photocoagulation for ME Secondary to BRVO	N/A	completed	80	Beijing Hospital	Feb 2017
NCT02953938	ZIPANGU	Study to Show a Superior Benefit in Terms of Reduction of Ranibizumab Injections in Patients Receiving Ranibizumab Plus Laser Photocoagulation Combination Therapy Without Loss of Efficacy and Safety	P4	completed	59	Novartis Pharmaceuticals	Dec 2016
NCT02914626		Intravitreal Ranibizumab (Lucentis®) for Neovascular Glaucoma- a Randomized Controlled Study	P3	unknown	28	LEANDRO CABRAL ZACHARIAS	Oct 2016
NCT02294656		Acute Pseudophakic Cystoid Macular Edema Treatment Trial: Intravitreal Ranibizumab Versus Triamcinolone Acetonide	P1	completed	4	Soll Eye	Nov 2014
NCT02665689	DORO	Influence of Diabetes Control on Treatment of Diabetic Macular Edema With Ranibizumab	P4	terminated	4	Prof. Dr. Antonia M. Joussen	Jan 2016
NCT03148132		VEGF Concentrations After Intravitreal Bevacizumab vs Ranibizumab as a Treatment for Type 1 ROP	P4	completed	16	Universidad Autonoma de San Luis Potosí	May 2017
NCT02302989	PROTECT	Prophylactic Ranibizumab for Exudative Age-Related Macular Degeneration	P1/P2	completed	4	Leonard Feiner, MD, PhD	May 2015
NCT03042871	SMILE	Dosing Strategy of Intravitreal Ranibizumab for Pathological Myopia Choroidal Neovascularization	P4	completed	54	Zhongshan Ophthalmic Center, Sun Yat-sen University	Apr 2015
NCT01972763	RESCUE	Ranibizumab for Recalcitrant Wet Age-related Macular Degeneration in Eyes Previously Switched From Bevacizumab and/or Ranibizumab to Aflibercept.	P1/P2	completed	12	Northern California Retina Vitreous Associates	Oct 2013
NCT03115255		Serum Vascular Endothelial Growth Factor in Infants With Intravitreal Ranibizumab	N/A	completed	17	Xinhua Hospital, Shanghai Jiao Tong University School of Medicine	May 2017
NCT03458923		Intravitreal Diclofenac Versus Intravitreal Ranibizumab for the Treatment of Diabetic Macular Edema.	P4	unknown	30	Cairo University	Jan 2015
NCT02611778	COLUMBUS-AMD	Efficacy and Safety of the Biosimilar Ranibizumab FYB201 in Comparison to Lucentis in Patients With Neovascular Age-related Macular Degeneration	P3	completed	712	Bioeq GmbH	Dec 2015
NCT03590444	DME	Treatment of Diabetic Macular Edema (DME) With Anti-VEGF and Focal Laser	P4	completed	50	Hospital Hietzing	Apr 2017
NCT02448446		The Effect of Intravitreal Ranibizumab on Visual Acuity and Hard Exudate Resolution in the Treatment of Diabetic Macular Edema With Center Involved Edema and Lipid Exudates	P1/P2	completed	25	South Coast Retina Center; Carson, McBeath, Boswell, Inc.	Aug 2015
NCT01934556	TREX-DME	A Safety and Efficacy Trial of a Treat and Extend Protocol Using Ranibizumab With and Without Laser Photocoagulation for Diabetic Macular Edema	P1/P2	completed	150	Palmetto Retina Center, LLC	Nov 2013
NCT02707575		Cytokeratin 8 Level in Age-related Macular Degeneration	—	completed	58	Gangnam Severance Hospital	Apr 2016
NCT02131350		Combination Treatment of Intravitreal Ranibizumab, Focal/Grid Laser and Panretinal Photocoagulation in Patients With Diabetic Macula Edema	P4	completed	40	Shinshu University	Apr 2014
NCT03038880	STAIRWAY	Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration	P2	completed	76	Hoffmann-La Roche	Jan 2017
NCT02329132		Change Oxygen Consumption Following Intravitreal Treatment of Lucentis (Ranibizumab) in Eyes With Diabetic Macular Edema	—	completed	30	Kagawa University	Nov 2015
NCT01489189	Protocol S	Prompt Panretinal Photocoagulation Versus Ranibizumab+Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy	P3	completed	305	Jaeb Center for Health Research	Mar 2012
NCT02522897	PEARL	Evaluation of the "Treat-and-extend" Scheme in Patients With Retinal Vein Occlusion (RVO) With and Without LASER Treatment of Ischaemic Retinal Areas	P4	unknown	60	PD. Dr. med. Armin Wolf	Aug 2015
NCT02530918		Study of DS-7080a for the Treatment of Macular Degeneration	P1	completed	56	Daiichi Sankyo	Jul 2015
NCT02727881	MAKO	Efficacy and Safety Study of Squalamine Ophthalmic Solution in Subjects With Neovascular AMD	P3	unknown	230	Ohr Pharmaceutical Inc.	Apr 2016
NCT02634970	CANARI	CANadian Study in Patients With Wet AMD, Evaluating the Efficacy and Safety of Switching From Intravitreal Aflibercept to RanIbizumab	P4	withdrawn	0	Novartis Pharmaceuticals	Mar 2016
NCT02462304	END-DME	To Compare Anti-VEGF Monotherapy With Anti-VEGF and EPM Grid Laser Combination Therapy for Diabetic Macular Edema	P4	unknown	60	The University of Hong Kong	Jun 2015
NCT02059772	ReCaLL	Combination of Standard Lucentis Therapy With Micropulse Diode Laser for the Treatment of Diabetic Macular Edema	P4	unknown	25	GWT-TUD GmbH	Apr 2014
NCT01795209	RVOFV	Ranibizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion in Patients With Fair Vision	P4	terminated	19	Seoul National University Bundang Hospital	Jan 2013
NCT01213667	RESPONSE	Genetics in Non-response to Anti-VEGF Treatment in Exudative AMD	P4	unknown	110	University of Cologne	Jan 2010
NCT02699450	BOULEVARD	A Study of Faricimab (RO6867461) in Participants With Center-Involving Diabetic Macular Edema	P2	completed	229	Hoffmann-La Roche	Apr 2016
NCT02375971	RAINBOW	RAINBOW Study: RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity	P3	completed	224	Novartis Pharmaceuticals	Dec 2015
NCT01594281	PRIDE	Multicenter 12 Months Clinical Study to Evaluate Efficacy and Safety of Ranibizumab Alone or in Combination With Laser Photocoagulation vs. Laser Photocoagulation Alone in Proliferative Diabetic Retinopathy (PRIDE)	P2	completed	107	Novartis Pharmaceuticals	Dec 2012
NCT02130024	RIVAL	A Comparison of Ranibizumab and Aflibercept for the Development of Geographic Atrophy in (Wet) AMD Patients	P4	completed	281	Novartis Pharmaceuticals	Apr 2014
NCT02843490	CAPTAIN	Functional and Structural Outcomes in Neovascular Age-related Macular Degeneration	P4	completed	71	Johannes Gutenberg University Mainz	Aug 2016
NCT02363621		Evaluation of Inflammation and Pain Post Injection of Ranibizumab vs Aflibercept in Patients With DME	P2	completed	101	Arshad Khanani	Jan 2015
NCT01941329	PROTEUS	Prospective, Randomized, Multicentre, Open-label, Phase II / III Study to Assess Efficacy and Safety of Ranibizumab 0.5 mg Intravitreal Injections Plus Panretinal Photocoagulation (PRP) Versus PRP in Monotherapy in the Treatment of Subjects With High Risk Proliferative Diabetic Retinopathy.	P2/P3	completed	94	Association for Innovation and Biomedical Research on Light and Image	Apr 2014
NCT02878681	TIDE DME	24 Week Study to Compare Systemic VEGF-levels of Ranibizumab and Aflibercept in DME.	P4	withdrawn	0	Novartis Pharmaceuticals	Sep 2016
NCT02857491		Intravitreal Injection of Ranibizumab Versus Sham Before Vitrectomy in Patients With Proliferative Diabetic Retinopathy	N/A	completed	90	Sun Yat-sen University	Jul 2014
NCT02484690	AVENUE	A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)	P2	completed	273	Hoffmann-La Roche	Aug 2015
NCT02161575	SAFARI	Safety and Efficacy of Switching From Aflibercept to Ranibizumab in Patients With nAMD	P4	completed	103	Novartis Pharmaceuticals	Aug 2014
NCT02979665		Changes to the Retina Following Anti-VEGF Treatments for Diabetic Macular Edema	—	completed	51	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	Sep 2014
NCT02067013	ARK	Analysis of Aqueous and Vitreous Humor	P2	unknown	45	California Retina Consultants	Jul 2015
NCT03261635		Ranibizumab Plus Indomethacin	P4	completed	58	Università degli Studi di Brescia	Jan 2016
NCT02281292		A Study of the Safety and Tolerability of Intravitreal LKA651 in Patients With Diabetic Macular Edema	P1	withdrawn	0	Alcon Research	Dec 2015
NCT03385382	LED	Ranibizumab Versus Dexamethasone Implant in Diabetic Macular Edema	—	completed	40	G. d'Annunzio University	Dec 2016
NCT02257632	TIDE AMD	Systemic Vascular Endothelial Growth Factor (VEGF) Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Neovascular Age-related Macular Degeneration	P4	completed	41	Novartis Pharmaceuticals	Apr 2015
NCT02366468	DIVERSE	Study of Efficacy of Ranibizumab in Different Regimens in Patients With Diabetic Macula Edema	P4	completed	135	Novartis Pharmaceuticals	Feb 2015
NCT01945866		Phase II Combination Steroid and Anti-VEGF for Persistent DME	P2	completed	129	Jaeb Center for Health Research	Feb 2014
NCT02328118	RaTAPDR	25-Gauge Vitrectomy With Ranibizumab or Triamcinolone Acetonide on Proliferative Diabetic Retinopathy in China	P2/P3	unknown	120	JUNYAN ZHANG	Feb 2015
NCT01958918	SALT	Efficacy of Ranibizumab Prn Treatment Compared to Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability in Patients With Wet AMD	P4	completed	712	Novartis Pharmaceuticals	Oct 2013
NCT01552408	DAVE	Efficacy & Safety Trial of Intravitreal Injections Combined With PRP for CSME Secondary to Diabetes Mellitus (DAVE)	P1/P2	completed	29	David M. Brown, M.D.	Mar 2012
NCT02107131	ERASER	Performance Assessment Tests in Working Individuals With DME Following Treatment With Ranibizumab	P4	completed	40	California Retina Consultants	Mar 2015
NCT02144662		Prognostic Factors for Visual Improvement in Patients Undergoing Intravitreal Ranibizumab for Retinal Vein Occlusion	N/A	completed	50	St. Marianna University School of Medicine	Mar 2014
NCT01846273	EVEREST II	Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV) Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy (vPDT)	P4	completed	321	Novartis Pharmaceuticals	Aug 2013
NCT01972789	FLUID	Comparison of Treatment Regimens Using Ranibizumab: Intensive (Resolution of Intra- and Sub-retinal Fluid) vs Relaxed (Resolution of Intra-retinal Fluid and/or Sub-retinal Fluid >200µm at the Foveal Centre)	P4	completed	349	Novartis Pharmaceuticals	Oct 2013
NCT01748292	T-REX	Treat & Extend Treatment With 0.5mg Ranibizumab vs Monthly Treatment With 0.5mg Ranibizumab	P3	completed	60	Charles C Wykoff, PhD, MD	Dec 2012
NCT02387957		A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)	P2	terminated	63	Ophthotech Corporation	Apr 2016
NCT02134457	CARE-ROP	Comparing Alternative Ranibizumab Dosages for Safety and Efficacy in Retinopathy of Prematurity	P2	completed	19	University Hospital Freiburg	Aug 2014
NCT02810808	ARTIS	Safety and Efficacy of Two Regimens of Ranibizumab 0.5 mg in Chinese Patients With Neovascular AMD	P4	unknown	115	Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	Dec 2013
NCT02259088	REFINE	A 12-month, Randomized, Efficacy and Safety Study of 0.5 mg Ranibizumab vs Laser in Chinese Diabetic Macular Edema (DME) Patients	P3	completed	384	Novartis Pharmaceuticals	Nov 2014
NCT03495765	CONTROL	To Evaluate the Comparative Efficacy of Lucentis (Ranibizumab) 0.5mg Intravitreal Injection in Patients With Diabetic Macular Oedema (DME) With Well Controlled and Poorly Controlled Diabetes Mellitus	P3	completed	160	Marsden Eye Specialists	Mar 2011
NCT02274259		Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With CRVO With a Treat& Extend Regimen	P4	completed	40	Anders Kvanta	Oct 2014
NCT02218177		Intraocular Cytokines in Non-responders to Ranibizumab Treatment for Neovascular AMD	—	completed	30	University Health Network, Toronto	Aug 2014
NCT02328209		Evaluation of the Simplified Treat And Extend Regimen Using Ranibizumab in Exudative Age Related Macular Degeneration	N/A	unknown	50	Mie University	Jun 2014
NCT01940900	E10030	A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy	P3	terminated	627	Ophthotech Corporation	Aug 2013
NCT01944839	E10030	A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy	P3	terminated	619	Ophthotech Corporation	Aug 2013
NCT01827722	ORION	Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion	P4	unknown	45	Valley Retina Institute	May 2013
NCT03393767		Time Course of Activity Signs at SD-OCT High Frequency Intravitreal Ranibizumab Treatment in CNV Due to AMD	P4	completed	30	Vista Klinik	Dec 2010
NCT01006538	MERLOT	Macular EpiRetinal Brachytherapy Versus Lucentis® Only Treatment (MERLOT)	P4	completed	363	King's College Hospital NHS Trust	Nov 2009
NCT02140411		Efficacy and Safety of Lucentis® (Ranibizumab Intravitreal Injections) in Chilean Patients With Diabetic Macular Edema.	P4	completed	21	Novartis Pharmaceuticals	Apr 2015
NCT01968239	RabOCT	Proof of Concept Study of Re-treatment in BRVO With Ranibizumab Guided by OCT	P2	completed	27	University of Leipzig	Oct 2013
NCT02258009	TIDE DME	Systemic VEGF Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema	P4	withdrawn	0	Novartis Pharmaceuticals	Oct 2015
NCT02355028		LHA510 Proof-of-Concept Study as a Maintenance Therapy for Patients With Wet Age-Related Macular Degeneration	P2	completed	136	Alcon, a Novartis Company	Mar 2015
NCT02511067	READ-4	Ranibizumab for Edema of the mAcula in Diabetes: Protocol 4 With Tocilizumab: The READ-4 Study	P2	withdrawn	0	University of Nebraska	Oct 2016
NCT02358889	EMERGE	Study Evaluating Intravitreal hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration	P2	completed	88	Iconic Therapeutics, Inc.	Feb 2015
NCT01476449		Dosing Study of Ranibizumab for Diabetic Retinal and Macular Edema	P2	completed	20	Retina Vitreous Associates of Florida	Nov 2011
NCT00765921		Ranibizumab in Combination With Proton Beam Irradiation for Choroidal Melanoma	P1	completed	40	Massachusetts Eye and Ear Infirmary	Jun 2008
NCT01922102	Brilliance	Efficacy and Safety of Ranibizumab 0.5 vs Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia	P3	completed	457	Novartis Pharmaceuticals	Sep 2013
NCT02302079	VIDI	A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema (DME)	P2	completed	96	Astellas Pharma Europe B.V.	Jan 2015
NCT02296567		Comparison of Pharmacokinetics of and Effect on Systemic VEGF Levels in Age Related Macular Degeneration Patients	P2/P3	unknown	80	East Florida Eye Institute	Dec 2014
NCT02034006	OLIMPIC	A Study of the Criteria Establishing the Need for Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia.	P3	completed	200	Novartis Pharmaceuticals	Jun 2014
NCT02577107	RELIANCE	Head to Head Study of Anti-VEGF Treatment.	P4	completed	12	Novartis Pharmaceuticals	Jan 2016
NCT02933905		Influence of the Vitreomacular Interface on the Progression of the Diabetic Macular Edema After Anti-VEGF Injection	—	completed	38	Fundació Institut Germans Trias i Pujol	Jan 2014
NCT04018833	SWITCH	Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema	—	completed	40	Bernardete Pessoa MD	Jan 2012
NCT01986907	TWEYES	Safety and Tolerability of Ranibizumab in Mono/Bilateral Wet Age Related Macular Degeneration (w-AMD) Patients in Eyes With BCVA<2/10 and/or 2nd Affected Eye	P4	completed	1,049	Novartis Pharmaceuticals	Mar 2014
NCT01030770		Preoperative Intravitreal Ranibizumab for Persistent Diabetic Vitreous Haemorrhage:	P2/P3	completed	25	King's College Hospital NHS Trust	Jul 2010
NCT01982435	REACT	Safety and Efficacy of Ranibizumab for Diabetic Macular Edema	P1/P2	completed	27	Justis Ehlers	Jun 2014
NCT02398500		Safety Tolerability and Efficacy of Intravitreal LMG324 in the Treatment of Neovascular Age-Related Macular Degeneration	P1/P2	terminated	25	Alcon Research	Jul 2015
NCT02511613		Effect of Squalamine Lactate Ophthalmic Solution, 0.2% in Subjects With Neovascular Age-Related Macular Degeneration	P2	withdrawn	0	Ohr Pharmaceutical Inc.	Jul 2015
NCT01318941	LUMINOUS	Observe the Effectiveness and Safety of Ranibizumab in Real Life Setting	—	completed	30,490	Novartis Pharmaceuticals	Mar 2011
NCT02698566	PFS	A Study in Patients With Neovascular Age Related Macular Degeneration or Macular Edema Secondary To Retinal Vein Occlusion to Evaluate Usability of the Ranibizumab (Lucentis®) Prefilled Syringe (PFS)	P3	completed	35	Genentech, Inc.	Mar 2016
NCT01914159	RIP	Ranibizumab In Pigment Epithelium Tears Secondary To Age-Related Macular Degeneration Study	P2	completed	24	University Hospital, Bonn	Feb 2013
NCT01976338	Blossom	Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Branch Retinal Vein Occlusion (BRVO)	P3	completed	283	Novartis Pharmaceuticals	Nov 2013
NCT01976312	Camellia	Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO)	P3	completed	252	Novartis Pharmaceuticals	Nov 2013
NCT01908816	ECLIPSE	An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases.	P3	completed	270	Novartis Pharmaceuticals	Sep 2013
NCT02181504		A Study of Abicipar Pegol in Japanese Patients With Neovascular Age-related Macular Degeneration	P2	completed	25	Allergan	Sep 2014
NCT02169648		Development of Intravitreal Ranibizumab by Determining the Pathogenesis of Macular Edema With Retinal Vein Occlusion	N/A	unknown	100	Tokyo Medical University	Dec 2013
NCT01162746		Comparison of Ranibizumab Monotherapy and Ranibizumab Combination Therapies in Recurrent or Persistent Choroidal Neovascularization Secondary to Age-related Macular Degeneration	P2	completed	40	Medical University of Vienna	Oct 2011
NCT01428388	CRAVE	Bevacizumab Versus Ranibizumab in Treatment of Macular Edema From Vein Occlusion	N/A	completed	150	Barnes Retina Institute	Sep 2011
NCT00976222		Intravitreal Ranibizumab in Retinal Pigment Epithelial Detachments	P4	completed	40	University Hospital Muenster	Dec 2008
NCT02646670		Efficacy of Ranibizumab Therapy With Aflibercept in Patients With Diabetic Macular Edema	P4	completed	20	Instituto de Olhos de Goiania	Jul 2015
NCT01840410		Assess the Efficacy/Safety of Intravitreal Ranibizumab in Patients With Vision Loss Due to Choroidal Neovascularization.	P3	completed	183	Novartis Pharmaceuticals	Sep 2013
NCT02127684		Frequent Dosing Regimen of Lucentis for Subjects With Persistent Diabetic Macular Edema Despite Standard antiVEGF Dosing	P2	withdrawn	0	Maturi, Raj K., M.D., P.C.	—
NCT01775124	DRAGON	Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With nAMD (Age Related Macular Degeneration)	P4	completed	332	Novartis Pharmaceuticals	Feb 2013
NCT01948830	TREND	Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD	P3	completed	650	Novartis Pharmaceuticals	Dec 2013
NCT02641457		Intravitreal Aflibercept or Ranibizumab for Rubeosis Iridis	P3	completed	2	Instituto de Olhos de Goiania	Mar 2014
NCT01710839	WAVE	Widefield Angiography Guided Targeted-retinal Photocoagulation Combined With Anti VEgf Intravitreal Injections for the Treatment of Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion	P4	completed	30	Charles C Wykoff, PhD, MD	Oct 2012
NCT01676506	AMD	Genetic Polymorphisms in Ranibizumab Treatment in Wet Age-Related Macular Degeneration (AMD)	N/A	unknown	300	Russian Academy of Medical Sciences	Oct 2011
NCT01846299		To Assess the Efficacy and Safety of Intravitreal Ranibizumab in People With Vision Loss Due to Macular Edema	P3	completed	181	Novartis Pharmaceuticals	Oct 2013
NCT01994291		A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema	P2	terminated	199	Pfizer	Nov 2013
NCT02055911		Retinal Ganglion Cell Function After Intravitreous Ranibizumab in Patients With Diabetic Macular Edema	P4	withdrawn	0	Federal University of São Paulo	Mar 2014
NCT03459144		Comparison of PDT, Intravitreal Ranibizumab and Combination for Polypoidal Choroidal Vasculopathy Under 1+PRN Regimen	N/A	completed	60	Sun Yat-sen University	Dec 2012
NCT01780935	OCTAVE	Efficacy and Safety of Two Treatment Regimens of 0.5 mg Ranibizumab Intravitreal Injections Guided by Functional and/or Anatomical Criteria, in Patients With Neovascular Age-related Macular Degeneration	P3	completed	671	Novartis Pharmaceuticals	Jun 2013
NCT02291887		Genetic Analysis of Patients Responsive to Ranibizumab But Resistant to Aflibercept	—	completed	13	Associated Retinal Consultants, Michigan	Dec 2014
NCT02527733		Retinal Sensitivity in BRVO After Anti-VEGF Therapy	P4	unknown	50	Fukushima Medical University	Jun 2015
NCT02222207	DREAM	Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration	P2	terminated	52	Bayer	Oct 2014
NCT02186119		A Study of Abicipar Pegol in Patients With Diabetic Macular Edema	P2	completed	151	Allergan	Jul 2014
NCT01581151		Ozurdex With Rescue Lucentis for Treating Macular Edema Secondary to Retinal Vein Occlusion	N/A	unknown	30	Brian Burke, MPH	Sep 2011
NCT02050828	TIME-2	The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema	P2	completed	144	Aerpio Therapeutics	Jan 2014
NCT02474225		Intraocular Pressure Change Following Intravitreal Injection of Anti-vascular Endothelial Growth Factor Agent	—	completed	70	Prince of Songkla University	Dec 2013
NCT01599650	BRIGHTER	Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion	P3	completed	455	Novartis Pharmaceuticals	May 2012
NCT01243086	STAR	OZURDEX in Age Related Macular Degeneration as Adjunct to Ranibizumab	P2	completed	10	McMaster University	Mar 2011
NCT01771081	POLARIS	Evaluation of Changes in Visual Acuity in Patients With Diabetic Macular Edema (DME) Starting Treatment With an Approved Anti-VEGF Therapy	—	completed	911	Bayer	Apr 2013
NCT01319188	RATE	Ranibizumab and the Risk of Arterial Thromboembolic Events	P4	terminated	380	Ural State Medical University	Jun 2010
NCT01003106	RELATE	Ranibizumab DosE Comparison and the Role of LAser in REtinal Vein Occlusions	P1/P2	completed	81	Peter A Campochiaro, MD	Nov 2009
NCT00593450		Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial	P3	completed	1,208	University of Pennsylvania	Feb 2008
NCT02032173	CONSTELLATION	Efficacy and Safety of Lucentis® Use in Patients With Diabetic Macular Edema Evaluating a Spaced Out Follow-up After Intensive Treatment Phase	P3	terminated	31	Novartis Pharmaceuticals	May 2014
NCT02181517		A Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration	P2	completed	25	Allergan	Jul 2014
NCT01535261	CRYSTAL	Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion	P3	completed	357	Novartis Pharmaceuticals	Feb 2012
NCT01402544	COMPASS	Clinical Assessment Of Age-related Macular Degeneration Patients After Early Diagnosis and Treatment With Ranibizumab	P2/P3	terminated	20	University of California, San Diego	Jul 2011
NCT01674569		Pilot Study of X-82 in Patients With Wet AMD	P1/P2	completed	35	Tyrogenex	Oct 2012
NCT01610557		Ranibizumab and Bevacizumab for Diabetic Macular Edema	P2	completed	56	National Eye Institute (NEI)	May 2012
NCT01469156		Safety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal Vasculopathy	P1/P2	completed	20	Southeast Retina Center, Georgia	Sep 2011
NCT01849692		ESBA1008 Microvolume Study	P2	completed	107	Alcon Research	Jun 2013
NCT01845844	ROTATE	Ranibizumab For Persistent Diabetic Macular Edema After Bevacizumab	P1/P2	unknown	30	Southeast Retina Center, Georgia	Apr 2013
NCT02614937		Study of Squalamine Lactate for the Treatment of Macular Edema Related to Retinal Vein Occlusion	P1/P2	completed	20	Ohr Pharmaceutical Inc.	Apr 2013
NCT02647515		Intravitreal Ranibizumab Injection as Adjuvant in the Treatment of Postvitrectomy Diabetic Vitreous Hemorrhage Accompanied by Neovascular Glaucoma	P4	completed	18	Ruijin Hospital	Jan 2013
NCT02372916		Geographic Atrophy and Intravitreal Ranibizumab Injections	—	unknown	90	University Health Network, Toronto	Nov 2014
NCT01246089		Ranibizumab for Myopic Neovascularization	P4	unknown	20	Instituto de Olhos de Goiania	Jul 2009
NCT01427751		Safety and Efficacy Study of Ozurdex® Compared to Lucentis® in Patients With Branch Retinal Vein Occlusion	P4	completed	307	Allergan	Oct 2011
NCT01565148	iDEAL	A Randomized, Multi-center, Phase II Study of the Safety, Tolerability and Bioactivity of Repeated Intravitreal Injections of iCo-007 as Monotherapy or in Combination With Ranibizumab or Laser Photocoagulation in the Treatment of Diabetic Macular Edema (the iDEAL Study)	P2	terminated	185	Johns Hopkins University	Feb 2012
NCT01363570	AMD	Evaluation of Wet Age-Related Macular Degeneration (AMD) Genetic Profile Interactions With Ranibizumab Treatment Outcomes	N/A	completed	70	McMaster University	Jan 2012
NCT02342392		Intralesional Ranibizumab on Pterygium Vascularity, Size and Recurrence Rate: a Pilot Study	P2/P3	completed	36	Universiti Sains Malaysia	Sep 2012
NCT00661583	OCTOPUS	Use of Ranibizumab With Mitomycin C During Trabeculectomy	P1/P2	completed	30	University of Colorado, Denver	Apr 2008
NCT01884597	PEARL2	Investigator Sponsored Trial of Polypoidal Choroidal Vasculopathy (PCV) Evaluation Assessing High-Dose Ranibizumab Prospectively (PEARL2)	P1/P2	completed	24	Hawaii Pacific Health	Nov 2010
NCT01127360	LUCAS	LUCAS (Lucentis Compared to Avastin Study)	P4	completed	420	Oslo University Hospital	Mar 2009
NCT01823965		Intravitreal Injections of Ranibizumab With Deferred Laser Grid Laser Photocoagulation for Treatment of Diabetic Macular Edema With Visual Impairment	P2	completed	35	Poitiers University Hospital	Oct 2011
NCT03409250		SD-OCT-guided Intravitreal Ranibizumab Treatment in Choroidal Neovascularization Due to Myopia	P4	completed	20	Vista Klinik	Jun 2011
NCT01169909		Efficacy and Safety of Sub-tenon Ranibizumab for Recurrent Pterygia	P1	completed	10	University of New Mexico	Aug 2010
NCT01564108		The LIMO Study, Lucentis for Treatment of Uveitic Patients With Refractory Cystoid Macular Oedema	P2	completed	10	Moorfields Eye Hospital NHS Foundation Trust	May 2012
NCT01112085	MINIMA-2	MIcrodoses of raNIbizumab in Diabetic MAcular Edema (MINIMA-2)	P2	completed	72	Especialistas en Retina Medica y Quirurgica Grupo de Investigacion	Apr 2010
NCT00931489	Antibody	Retinal and Retinal Pigment Epithelium (RPE) Autoimmunity in Age-related Macular Degeneration (AMD)	P2	completed	131	Lawrence S. Morse, MD	Aug 2009
NCT01926977		Evaluation of Pain and Inflammation After Injection of Lucentis vs Eylea for Treatment of Wet Macular Degeneration	P1/P2	completed	100	Arshad Khanani	Sep 2013
NCT01247220	Revolution	REtinal Vein OccLUsion Treatment With Scatter Laser Guided by UWFA in combiNAtion With Ranibizumab Study	P2	completed	12	Retina Associates of Florida, P.A.	Nov 2010
NCT02118831		Systemic Pharmacokinetics Following Intravitreal Injections of Anti-VEGF	P1/P2	completed	56	California Retina Consultants	Mar 2012
NCT01397409	AMD	Evaluation of AGN-150998 in Exudative Age-related Macular Degeneration (AMD)	P2	completed	271	Allergan	Sep 2011
NCT01269151	LucERG	Ranibizumab Short- and Log-term Effects on Retinal Function in wAMD	N/A	completed	20	University of Luebeck	Oct 2010
NCT03334513		Refractive Error and Biometry in Retinopathy of Prematurity	—	completed	35	San Ni Chen	Apr 2011
NCT00892398		Trabeculectomy With Mitomycin C Associated With Sub-conjunctival Injection of Ranibizumab	N/A	completed	242	Maisonneuve-Rosemont Hospital	Mar 2009
NCT01471691	RAVEN	Intravitreal Ranibizumab 0.5MG, or 1.0mg for RVO With Macular Edema Previously Receiving Bevacizumab	P1/P2	completed	14	Hanscom, Thomas, M.D.	Nov 2011
NCT00444600	LRT for DME	Laser-Ranibizumab-Triamcinolone for Diabetic Macular Edema	P3	completed	691	Jaeb Center for Health Research	Mar 2007
NCT01492400		Safety and Efficacy Study of Dexamethasone Versus Ranibizumab in Patients With Diabetic Macular Edema	P2	completed	363	Allergan	Mar 2012
NCT02060604		Pilot Study of Ranibizumab With and Without Ketorolac Eyedrops for Exudative Age-related Macular Degeneration	P4	completed	60	Università degli Studi di Brescia	Dec 2012
NCT01472510		Ranibizumab in Residual Diabetic Macular Edema Following Previous Anti-VEGF Therapy	P2	completed	20	Vitreo-Retinal Associates, PC	Dec 2011
NCT01396083	COMRADE-C	Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Central Retinal Vein Occlusion (CRVO)	P3	completed	243	Novartis Pharmaceuticals	Aug 2011
NCT02036723	GALATIR	Safety and Efficacy Study of BCD-021 Compared to Lucentis® in Patients With Neovascular Wet Age-related Macular Degeneration	P3	withdrawn	0	Biocad	—
NCT02091505	CRVO	Predictive Factors of Ranibizumab Treatment in Macular Edema With CRVO	N/A	unknown	30	Mie University	Dec 2013
NCT01824043		Use of Intravitreal Ranibizumab in the Treatment of Vitreous Hemorrhage	P4	unknown	20	Hospital Regional de São José - Dr. Homero de Miranda Gomes	Mar 2013
NCT01280929	PRP	Prospective, Randomized, Multicenter, Open Label, Phase II Study to Access Efficacy and Safety of Lucentis® Monotherapy Compared With Lucentis® Plus Panretinal Photocoagulation (PRP) and PRP in the Treatment of Patients With High Risk Proliferative Diabetic Retinopathy	P2	completed	54	José Cunha-Vaz	Sep 2010
NCT01448018	CHIC-3	Hemodilution Versus Ranibizumab in Early-onset Central Retinal Vein Occlusion	P4	completed	45	Centre Hospitalier Intercommunal Creteil	Jan 2010
NCT00931125	VITARM	Safety and Efficacy of Intravitreal Ranibizumab as a Preoperative Adjunct Treatment Before Vitrectomy Surgery in Proliferative Diabetic Retinopathy (PDR) Compared to Vitrectomy Alone	P2	unknown	70	Attila Vajas	Mar 2009
NCT00657202		Ranibizumab for Neurofibromas Associated With Neurofibromatosis 1	Early P1	completed	11	Massachusetts General Hospital	Mar 2008
NCT01445899	MATISSE	PF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With/Without Ranibizumab in Diabetic Macular Edema (DME)	P2	completed	258	Quark Pharmaceuticals	Feb 2012
NCT01011374		Impact of Lucentis on Psychological Morbidity in Patients With Retinal Vein Occlusion	P1	unknown	45	Retina Associates of Cleveland, Inc	Nov 2009
NCT00667472		Combined Pulsed Dye Laser and Topical Ranibizumab for Treatment of Port Wine Stain Birthmarks	P1	withdrawn	0	University of California, Irvine	Mar 2008
NCT00533520	BGB/IST	Evaluation of Dosing Interval of Higher Doses of Ranibizumab	P4	completed	37	Brandon G. Busbee, MD	Sep 2007
NCT02164604	ROP	Lucentis to Treat Retinopathy of Prematurity (ROP) 3 Plus Disease	N/A	completed	6	Kantonsspital Aarau	Jan 2011
NCT00727753	AMD	VEGF-antagonism and Endothelial Function in Age-related Macular Degeneration (AMD)	—	completed	54	University of Zurich	Jul 2008
NCT00896779		Lucentis in Advanced Macular Degeneration	P2	completed	20	Steven R. Sanislo	Oct 2009
NCT00826618		Pilot Study of Ranibizumab (Lucentis) for Uveitic Cystoid Macular Edema	P1	completed	6	University of Miami	Jun 2008
NCT01661946		Bloodstream Absorption of Avastin and Lucentis After Injection Into the Eye	P3	completed	10	Queen's University	Aug 2012
NCT01968486		Reduced-fluence Verteporfin Photodynamic Therapy Plus Ranibizumab for Choroidal Neovascularization in Pathologic Myopia	P1	completed	60	University of Campania Luigi Vanvitelli	Jun 2012
NCT01396057	COMRADE-B	Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Branch Retinal Vein Occlusion (BRVO)	P3	completed	244	Novartis Pharmaceuticals	Jul 2011
NCT01028248		Lucentis for Macular Edema Associated With Central Retinal Vein Occlusion	P1	completed	20	California Retina Consultants	Jan 2010
NCT01933152	REVIEW	Study to Assess the EffectiVeness of exIsting Anti-vascular Endothelial groWth Factor (Anti-VEGF) Treatment Regimens in Patients With Wet Age-related Macular Degeneration	—	completed	137	Bayer	Aug 2012
NCT01292798	REEF	Ranibizumab 0.5mg and 2.0mg to Treat Diabetic Macular Edema in Patients With Poor Response to Bevacizumab	P1/P2	completed	43	California Retina Consultants	Mar 2011
NCT01257815	RELIGHT	Ranibizumab Treatment of Diabetic Macular Oedema With Bimonthly Monitoring After a Phase of Initial Treatment	P4	completed	111	Novartis Pharmaceuticals	Jan 2011
NCT01171976	RETAIN	Efficacy and Safety of Ranibizumab in Two "Treat and Extend" Treatment Algorithms Versus Ranibizumab As Needed in Patients With Macular Edema and Visual Impairment Secondary to Diabetes Mellitus	P3	completed	373	Novartis Pharmaceuticals	Sep 2010
NCT00545870		Bevacizumab Versus Ranibizumab for Diabetic Retinopathy	P3	completed	30	Ursula Schmidt-Erfurth, M.D.	Jun 2008
NCT01304693	AMD	ESBA1008 Safety, Tolerability and Effects in Wet Age-Related Macular Degeneration (AMD) Patients	P1/P2	completed	376	Alcon Research	Oct 2010
NCT01189019	HiPED	HiPED - High Dose Lucentis for Persistent Pigment Epithelial Detachments in Age-related Macular Degeneration	P2	terminated	40	Anne Fung MD	Aug 2010
NCT01135914	RESPOND	Safety, Efficacy and Cost-efficacy of Ranibizumab (Monotherapy or Combination With Laser) in the Treatment of Diabetic Macular Edema (DME)	P3	completed	241	Novartis Pharmaceuticals	Jul 2010
NCT01831947	RABIMO	Efficacy Study of Ranibizumab on Patients With Age-related Macular Degeneration.	P4	completed	40	Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH	Apr 2010
NCT01077401	READ 3	Ranibizumab for Edema of the Macula in Diabetes: Protocol 3 With High Dose - the READ 3 Study	P2	completed	152	Johns Hopkins University	Feb 2010
NCT01306981	RaDiVit	Ranibizumab in Diabetic Vitrectomy. A Prospective, Randomised Controlled Trial of Ranibizumab Pre-treatment in Diabetic Vitrectomy - a Pilot Study	P4	completed	30	Moorfields Eye Hospital NHS Foundation Trust	Mar 2011
NCT01248117	PEARL2	Safety Study of High-Dose Ranibizumab for Polypoidal Choroidal Vasculopathy	P1/P2	unknown	20	Retina Consultants of Hawaii	Nov 2010
NCT01810042		Indocyanine Angiographic Changes of Choroidal Neovascularization by Ranibizumab	P4	completed	49	Pusan National University Hospital	Oct 2010
NCT00407355	LVO	Ranibizumab (Lucentis) for Macular Edema Secondary to Vein Occlusions	P1/P2	completed	40	Peter A Campochiaro, MD	Jan 2006
NCT00996437	N	Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy (N)	P2/P3	completed	261	Jaeb Center for Health Research	Jun 2010
NCT01025232	SAVE	A Study of Intravitreal Injections of 2.0mg Ranibizumab in Subjects With Chronic Fluid On OCT Post Multiple Injections With Ranibizumab (Super-dose Anti-VEgf SAVE Trial)	P1/P2	terminated	88	David M. Brown, M.D.	Dec 2009
NCT01464723	SEAGUL2	Study EvAluating Genotypes While Using Lucentis 2	P4	completed	66	University of California, San Diego	May 2008
NCT01669447		Evaluation of Changes in the Parameters of Optical Coherence Tomography After Intravitreal Injection of Lucentis	P4	unknown	20	Osias Francisco de Souza	Sep 2012
NCT01198327	RETAIN	Extended Follow-up of Patients With Macular Edema Due to Retinal Vein Occlusion	P3	completed	66	Peter A Campochiaro, MD	Aug 2010
NCT00831350	PADDLE	Posterior Vitreous Detachment (PVD) Assessment During Dual Retinal Vein Occlusion (RVO) Lucentis Evaluations	P2	completed	32	Barnes Retina Institute	Apr 2009
NCT01922154		Intravitreous Ranibizumab as Adjunctive Treatment for Trabeculectomy in Neovascular Glaucoma	P4	completed	15	Siriraj Hospital	Feb 2009
NCT00793923	Lucedex	A Prospective Study Comparing Ranibizumab Plus Dexamethasone Combination Therapy Versus Ranibizumab Monotherapy for Wet AMD	P1/P2	completed	40	Subhransu K. Ray, M.D., Ph.D.	Jan 2008
NCT01255774	FVF4193s	Serial Retinal Thickness Changes And Scotoma Size Measured With Lucentis Therapy	P3	unknown	20	The New York Eye & Ear Infirmary	Jun 2007
NCT00440609		Study Comparing 0.5mg of Ranibizumab and Higher Doses in the Treatment of Clinically Significant Diabetic Macular Edema	P1/P2	completed	50	Philip J. ferrone, M.D.	Mar 2007
NCT01334879		High Dose Intravitreal Ranibizumab for Recalcitrant Radiation Retinopathy	P1	completed	10	The New York Eye Cancer Center	May 2011
NCT01297569	OPTIMAL	Ranibizumab "Treat and Extend" in Diabetic Macular Edma	P4	completed	7	Novartis Pharmaceuticals	Jan 2011
NCT01447043	AURA	Study to Assess the Effectiveness of Existing Anti vascUlar Endothelial Growth Factor (Anti VEGF) in Patients With Wet Age-related Macular Degeneration (wAMD) (AURA)	—	completed	2,609	Bayer	Jan 2009
NCT00473330	RISE	A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RISE)	P3	completed	377	Genentech, Inc.	Jun 2007
NCT01277302		A Study Evaluating Dosing Regimens for Treatment With Intravitreal Ranibizumab Injections in Subjects With Macular Edema Following Retinal Vein Occlusion	P4	completed	202	Genentech, Inc.	Feb 2011
NCT01205035	HD-LIPT	High-Dose Lucentis (Ranibizumab 2.0mg) for the Treatment of Nonproliferative Idiopathic Parafoveal Telangiectasia	P2	completed	6	Eye Center of Northern Colorado, P.C.	Oct 2010
NCT01134055		Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration	P2	completed	510	GlaxoSmithKline	Jun 2010
NCT01487629	IBERA-DME	Bevacizumab Versus Ranibizumab for the Treatment of Diabetic Macular Edema	P2	unknown	53	University of Sao Paulo	Apr 2010
NCT01325181		Ranibizumab Versus Low-fluence Photodynamic Therapy in the Treatment of Chronic Central Serous Chorioretinopathy	P1/P2	completed	34	Jang Won Heo	Jul 2009
NCT00473382	RIDE	A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RIDE)	P3	completed	382	Genentech, Inc.	Jun 2007
NCT01746563		Intravitreal Ranibizumab Combined With Panretinal Photocoagulation in Patients With Proliferative Diabetic Retinopathy	P1/P2	completed	30	University of Sao Paulo	May 2011
NCT01315275	LUDIC	A Clinical Study in Current Medical Practice of the Efficacy and Safety of Ranibizumab 0.5mg in Diabetic Patients Presenting a Visual Impairment Due to Macular Edema	P4	completed	394	Novartis Pharmaceuticals	Feb 2011
NCT01217944		Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia	P3	completed	277	Novartis Pharmaceuticals	Oct 2010
NCT01225146	RAVE2	Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2)	P1	terminated	8	David M. Brown, M.D.	Oct 2010
NCT01251978		Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)	P2	completed	10	New England Retina Associates	Jul 2010
NCT00891735	HARBOR	A Study of Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-related Macular Degeneration (HARBOR)	P3	completed	1,097	Genentech, Inc.	Jul 2009
NCT00749021		Ranibizumab for Treating Submacular Vascularized Pigment Epithelial Detachments	P1	completed	40	Clement K. Chan	Sep 2008
NCT00454389	CABERNET	A Study of Strontium90 Beta Radiation With Lucentis to Treat Age-Related Macular Degeneration	P3	unknown	494	NeoVista	Apr 2007
NCT01453920		Wet AMD Recurrence Rate in Patients Stable on Three Month Ranibizumab Dosing	P4	completed	44	University Health Network, Toronto	Nov 2011
NCT01253694		Ranibizumab as a Rescue Therapy for Diabetic Macular Edema	P2	withdrawn	0	New England Retina Associates	Mar 2011
NCT01500915	FUSION	FUSION Regimen: Combined Pro re Nata and Fixed Regimen Ranibizumab in Exudative Age-related Macular Degeneration	P4	completed	17	Institut de la Macula y la Retina	Nov 2010
NCT01223612	LUCIDATE	Lucentis (Ranibizumab) in Diabetic Macular Oedema: a Treatment Evaluation	P4	completed	37	Moorfields Eye Hospital NHS Foundation Trust	Oct 2010
NCT00557791	CARBON	Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD (CARBON)	P3	withdrawn	0	OPKO Health, Inc.	Nov 2009
NCT00680225		Lucentis as an Adjuvant Therapy With TTT-ICG Based in Choroidal Melanoma	P3	completed	10	New England Retina Associates	Sep 2007
NCT00726973	AMD	Pilot Study Reduced Fluence PDT /Visudyne With Ranibizumab vs Ranibizumab Monotherapy for Exudative Age-related Macular Degeneration (AMD)	N/A	withdrawn	0	Lahey Clinic	Dec 2006
NCT01635790	BRDME	Comparing the Effectiveness and Costs of Bevacizumab to Ranibizumab in Patients With Diabetic Macular Edema (BRDME)	P2/P3	unknown	246	Prof. dr. R.O. Schlingemann	Jun 2012
NCT01635803	BRVO	Comparing the Effectiveness and Costs of Bevacizumab to Ranibizumab in Patients With Retinal Vein Occlusions (BRVO)	P2/P3	unknown	296	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	Jun 2012
NCT01406639	HHT	Ranibizumab for the Management of Recurrent Nosebleeds in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)	P1	withdrawn	0	University of California, San Diego	Jul 2011
NCT01037348	REPAIR	Ranibizumab for the Treatment of Choroidal Neovascularisation (CNV) Secondary to Pathological Myopia (PM): an Individualized Regimen	P2	completed	65	Novartis	Jan 2010
NCT00885794	MORE	Microperimetry and Optical Coherence Tomography (OCT) With Lucentis for Diabetic Macular Edema (DME)	P2/P3	unknown	40	The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery	May 2008
NCT01626339		Effect of Intravitreal Anti-VEGF on Retinal Vessels Diameter	N/A	unknown	30	University of Malaya	Apr 2012
NCT01157065	RACE	Evaluation of AL-78898A in Exudative Age-Related Macular Degeneration	P2	completed	99	Alcon Research	Jun 2011
NCT01377597	RVO in Japan	Efficacy and Safety of Ranibizumab in Japanese Patients With Retinal Vein Occlusion	P3	completed	47	Novartis Pharmaceuticals	Jun 2011
NCT01148511	SALUTE	Comparison of Safety, Effectiveness and Quality of Life Outcomes Between Labeled Versus "Treat and Extend" Regimen in Turkish Patients With Choroidal Neovascularisation Due to Age-related Macular Degeneration (AMD)	P4	completed	99	Novartis Pharmaceuticals	Feb 2010
NCT00769145		Ranibizumab for the Inhibition of Neovascularization in the Cornea Following Corneal Transplant Surgery	P1	completed	5	University of Miami	Oct 2008
NCT00668785		Intravitreal Ranibizumab to Treat Macular Edema After Panretinal Photocoagulation (Phase II)	P2	terminated	6	Jumper, J. Michael, M.D.	Mar 2007
NCT02005432	IVR	PASCAL Laser Versus ETDRS Laser Associated With Intravitreal Ranibizumab (IVR) Versus Only IVR for Proliferative Diabetic Retinopathy	P4	unknown	31	University of Sao Paulo	Feb 2012
NCT01014468	AxL-2009	Bevacizumab Versus Ranibizumab in Age Related Macular Degeneration	P3	unknown	500	Instituto de Olhos de Goiania	Mar 2009
NCT01238393	LERM	Treatment of Epiretinal Membranes With Ranibizumab	N/A	completed	11	Queen's University	Nov 2010
NCT01115556	LAST	A Pilot Study to Evaluate the Role of High-dose Ranibizumab (2.0mg) in the Management of AMD in Patients With Persistent/Recurrent Macular Fluid Less Than 30 Days Following Treatment With Intravitreal Anti-VEGF Therapy (the LAST Study)	P1/P2	completed	9	Vitreous -Retina- Macula Consultants of New York	May 2010
NCT00768963		Ranibizumab for the Inhibition of Neovascularization in Pterygia	P1	completed	10	University of Miami	Oct 2008
NCT00687804	RESTORE	A 12 Month Core Study to Assess the Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema and a 24 Month Open-label Extension Study	P3	completed	345	Novartis	May 2008
NCT01069341		Use of Ranibizumab to Treat Rubeosis in Diabetics Prior to Cataract Surgery	P1	completed	4	Bhagat, Neelakshi, M.D., M.P.H.	Jul 2007
NCT00841581		Lucentis to Treat Pigment Epithelial Detachment	P2	completed	32	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	Dec 2008
NCT00403039		Intravitreal Ranibizumab Treatment of Central Retinal Vein Occlusion With Macular Edema	P1	completed	41	Vitreous -Retina- Macula Consultants of New York	Nov 2006
NCT00764738		Study Investigating OCT, Multifocal ERG, and Microperimetry in Monthly Versus PRN Ranibizumab in Neovascular Age-Related Macular Degeneration	P2/P3	completed	91	Retina Macula Institute	Oct 2008
NCT00709657		The Effect of a Single Intravitreal Anti-VEGF Therapy on Optic Nerve Head Perfusion	N/A	terminated	8	Medical University of Vienna	Mar 2008
NCT01638858		Treatment of Diabetic Macular Edema With 0.5mg Intraocular Ranibizumab (Lucentis)	N/A	completed	25	University of Luebeck	Oct 2011
NCT01249937	STAR	Sub-tenon Triamcinolone Acetonide in Age-Related Macular Degeneration as Adjunct to Ranibizumab	P2	unknown	30	University Health Network, Toronto	Jan 2011
NCT01123564	BRAVO	Efficacy and Safety of Lucentis for Clinically Significant Macular Edema Secondary to Central Retinal Vein Occlusion	P2	unknown	40	University of Pecs	Aug 2009
NCT00791427	FVF4154s	ERG/EOG Study in AMD Patients Treated With Ranibizumab	—	completed	10	Retina Center, Minnesota	Nov 2008
NCT00750399		Effect of Intravitreal Ranibizumab on Radiation Retinopathy Following Plaque Brachytherapy for Choroidal Melanoma	P1	completed	10	The New York Eye Cancer Center	Oct 2008
NCT00846625	SURFING	Study of Uveitic Macular Edema Treated With Ranibizumab or Steroids	P2	withdrawn	0	University of Utah	Nov 2009
NCT00989989	REVEAL	Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema	P3	completed	396	Novartis	Sep 2009
NCT01189526	BRVO	Comparison of Intravitreal Ranibizumab and Macular Laser Photocoagulation for ME Following Branch Retinal Vein Occlusion (BRVO)	P3	unknown	60	Seoul Retina Investigator Group	Jan 2009
NCT00637377	VIEW 2	Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD)	P3	completed	1,240	Bayer	Apr 2008
NCT00815360	RaScaL	Ranibizumab and Peripheral Scatter Laser in Patients With Diabetic Macular Edema and Peripheral Nonperfusion	P2	completed	22	Retina Associates of Florida, P.A.	Feb 2008
NCT01570608		Lucentis KAV Study	P3	completed	51	The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery	Mar 2007
NCT00407381	READ-2	The Ranibizumab for Edema of the mAcula in Diabetes-2 (READ-2) Study	P2	completed	126	Johns Hopkins University	Dec 2006
NCT01131585	RELATION	Safety and Efficacy of Ranibizumab in Diabetic Macular Edema	P3	terminated	128	Novartis Pharmaceuticals	Jun 2010
NCT00713518	MONET	Phase II Open Label Multicenter Study For Age Related Macular Degeneration Comparing PF-04523655 Versus Lucentis In The Treatment Of Subjects With CNV (MONET Study).	P2	completed	152	Quark Pharmaceuticals	Nov 2009
NCT01370135	LucNVG0108	Study to Evaluate the Effects of Ranibizumab (Lucentis) for Patients With Rubeosis and Neovascular Glaucoma	N/A	completed	20	University of Luebeck	Nov 2008
NCT00509795	VIEW1	Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)	P3	completed	1,217	Regeneron Pharmaceuticals	Aug 2007
NCT00618644		Ranibizumab for Neovascularization in Sickle Cell Retinopathy	N/A	withdrawn	0	Kresge Eye Institute	Jan 2010
NCT00570193	PBS	Photodynamic and Pharmacologic Treatment of CNV	P1/P2	completed	41	Mid-Atlantic Retina Consultations, Inc.	Dec 2006
NCT01360151		Aqueous Humor Level of Cytokines in Polypoidal Choroidal Vasculopathy and Change of Cytokines After Photodynamic Therapy	N/A	unknown	16	Seoul St. Mary's Hospital	Feb 2011
NCT01122511		Safety and Efficacy of Dexamethasone as Adjunctive Therapy to Ranibizumab in Subjects With Choroidal Neovascularization and Age-Related Macular Degeneration	P2	terminated	4	Allergan	Aug 2010
NCT00992563	AMD	WALTZ - Wet Age-Related Macular Degeneration (AMD) AL-39324 Treatment Examination	P2	completed	35	Alcon Research	Jun 2010
NCT00626782		Lucentis Versus Mitomycin C During Glaucoma Surgery	P2/P3	completed	24	Wills Eye	Jan 2008
NCT00685503		Ranibizumab Injections to Treat Macular Telangiectasia With New Blood Vessel Growth	P1	completed	1	National Eye Institute (NEI)	May 2008
NCT00685854		Ranibizumab Injections to Treat Macular Telangiectasia Without New Blood Vessel Growth	P1	completed	5	National Eye Institute (NEI)	May 2008
NCT00994799		Comparison of Intravitreal Ranibizumab and Macular Grid-pattern Laser for Treatment of Diabetic Macular Edema	—	unknown	50	Szeged University	Jul 2009
NCT01102946	IRaHi	Panretinal Photocoagulation (PRP) Plus Ranibizumab for Proliferative Diabetic Retinopathy	P2	completed	40	University of Sao Paulo	Feb 2009
NCT01015495	CNV	Ranibizumab Therapy for Choroidal Neovascularization (CNV) Asociated With Angioid Streaks	P1/P2	withdrawn	0	University of Illinois at Chicago	Dec 2009
NCT00644280		Ranibizumab in Preventing Failure of Ahmed Valve Glaucoma Surgery	N/A	terminated	11	University of California, San Francisco	Apr 2008
NCT00406471	RAVE	Rubeosis Anti-VEGF (RAVE) Trial for Ischemic Central Retinal Vein Occlusion	P1	completed	20	Greater Houston Retina Research	May 2005
NCT00470977	FVF4140S	Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy	P1/P2	completed	18	Manhattan Eye, Ear & Throat Hospital	May 2007
NCT00837330		Ranibizumab (Lucentis) for Polypoidal Choroidal Vasculopathy	P1/P2	completed	20	Southeast Retina Center, Georgia	May 2006
NCT00606138		Ranibizumab for Treatment of Persistent Diabetic Neovascularization Assessed by Wide-Field Imaging	P1/P2	completed	9	Rush University Medical Center	Jan 2008
NCT01256632	PVD	Evaluation of the Effect of Vitreous Composition Determined by Ultrasound and Optical Coherence Tomography (OCT) on Ranibizumab Therapy	N/A	completed	40	Vision Research Foundation	Oct 2007
NCT00406796	CRVO	Lucentis for Central Retinal Vein Occlusion (CRVO)	P1	completed	20	California Retina Consultants	Jan 2006
NCT00805233		Combination Ranibizumab and Bromfenac for Neovascular Age-related Macular Degeneration	P2	completed	30	Oregon Health and Science University	Dec 2008
NCT00681889	NV	Effectiveness and Safety of Topical Ranibizumab for Treatment of Corneal Neovascularization (NV)	P1	completed	9	Reza Dana, MD	Apr 2008
NCT00562406	RABAMES	Ranibizumab for Branch Retinal Vein Occlusion Associated Macular Edema Study (RABAMES)	N/A	completed	30	Klinikum Ludwigshafen	Nov 2007
NCT00456495		Effect of Ranibizumab on Malignant Conjunctival Neoplasia	P1	completed	5	The New York Eye Cancer Center	Mar 2007
NCT00424710	PEARL	Ranibizumab for Polypoidal Choroidal Vasculopathy (PCV)	P1	completed	17	Hawaii Pacific Health	Jan 2007
NCT00559715	VIBERA	Prevention of Vision Loss in Patients With Age-Related Macular Degeneration (AMD) by Intravitreal Injection of Bevacizumab and Ranibizumab	P3	unknown	366	Klinikum Bremen-Mitte, gGmbH	Aug 2008
NCT01442064		An Extension Study to Evaluate Safety and Tolerability of Ranibizumab in Macular Edema Secondary to Retinal Vein Occlusion (Cohort 2)	N/A	completed	608	Genentech, Inc.	Jul 2008
NCT00445003	LRTforDME+PRP	Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy	P3	completed	333	Jaeb Center for Health Research	Mar 2007
NCT00517010		Pilot Study of Lucentis Combined With Proton Beam Irradiation in Treating Wet Age-related Macular Degeneration	Early P1	completed	6	University of California, Davis	May 2007
NCT00492284	RADICAL	Reduced Fluence Visudyne-Anti-VEGF-Dexamethasone In Combination for AMD Lesions (RADICAL)	P2	completed	162	QLT Inc.	Jul 2007
NCT00775411	AMD	Safety and Efficacy of a New Therapy as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) in Subjects With Wet Age-Related Macular Degeneration (AMD)	P2	completed	44	Allergan	Nov 2008
NCT00676559	CAPTURE	Combined aPproach to Treatment Using Ranibizumab and Efalizumab for Diabetic Macular Edema Study: The CAPTURE DME Study	P1	withdrawn	0	Johns Hopkins University	Apr 2008
NCT01628354		Study to Investigate the Safety and Efficacy of Ranibizumab in Patients With Choroidal Neovascularisation Due to Causes Other Than Age Related Macular Degeneration	P4	completed	49	University of Melbourne	Feb 2008
NCT00546936		Ranibizumab Versus PDT for Presumed Ocular Histoplasmosis	P2	unknown	30	Barnes Retina Institute	Oct 2007
NCT00510965	CNV	Ranibizumab to Treat Choroidal Neovascularization (CNV) in Patients With Pseudoxanthoma Elasticum (PXE)	P2	completed	10	University Hospital, Bonn	Aug 2007
NCT00469352		A Study of Genetic and Environmental Factors and Their Effect on Response to Treatment With Lucentis (Ranibizumab) for Wet AMD	P3	completed	150	Oregon Health and Science University	May 2007
NCT00473642	PDT	Reduced Fluence Photodynamic Therapy (PDT) With Visudyne in Combination With Lucentis for Age-Related Macular Degeneration	P4	completed	31	Oklahoma State University Center for Health Sciences	May 2007
NCT00766337	EMERALD	Phase 2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Combination With Lucentis® in Patients With Age-Related Macular Degeneration	P2	terminated	62	Santen Inc.	Dec 2008
NCT00993525	INIPE	Intravitreal Ranibizumab For Persistent New Vessels In Diabetic Retinopathy(Inipe Study)	P1/P2	unknown	22	University of Sao Paulo	Sep 2008
NCT00599222	AMD	The Ranibizumab Plus Transpupillary Thermotherapy for Neovascular Age-Related Macular Degeneration (AMD) Study	P3	completed	100	Anders Kvanta	Feb 2008
NCT01201161	RANITRA	Ranibizumab for Diabetic Traction Retinal Detachment	P2	completed	19	University of Sao Paulo	Dec 2008
NCT00504959		Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration	P4	completed	234	Novartis	Jul 2007
NCT00527475	RAP	Ranibizumab and Reduced Fluence PDT for AMD	P2	completed	60	Texas Retina Associates	May 2007
NCT00813891		Efficacy of Ranibizumab in Combination With Photodynamic Therapy for Wet Age-Related Macular Degeneration	P4	unknown	180	McGill University Health Centre/Research Institute of the McGill University Health Centre	Jan 2009
NCT00942864	RVO	Effect of Intravitreal Ranibizumab Injection With Retinal Vein Occlusion (RVO)	P3	completed	40	Novartis Korea Ltd.	Dec 2008
NCT00498355	LIME	Lucentis for Inflammatory Macular Edema Trial	P1/P2	completed	7	University of California, San Francisco	Jul 2007
NCT00485836	CRUISE	A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion (CRUISE)	P3	completed	392	Genentech, Inc.	Jul 2007
NCT00590694	DETAIL	Lucentis for Age-related Macular Degeneration Pigment Epithelial Detachments	P2/P3	completed	15	Pacific Eye Associates	Oct 2006
NCT00390208	PDEX	Triple Therapy - PDT Plus IVD and Intravitreal Ranibizumab Versus Lucentis Monotherapy to Treat Age-Related Macular Degeneration	P2	completed	60	Bay Area Retina Associates	Aug 2006
NCT00486018	BRAVO	A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion (BRAVO)	P3	completed	397	Genentech, Inc.	Jul 2007
NCT00574093	Luvi	Efficacy and Safety Study of Lucentis (Ranibizumab) and Visudyne (Verteporfin) Combination Therapy in Neovascular AMD	P2	completed	15	Fondazione G.B. Bietti, IRCCS	Jan 2008
NCT00680498	CLOVER	Combination Lucentis and Ocular Photodynamic Therapy With Visudyne, With Evaluation-based Retreatment	P4	completed	10	Illinois Retina Associates	Feb 2007
NCT00436553		Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization	P3	completed	321	Novartis	Feb 2007
NCT00811200	TORR	Treatment Of Radiation Retinopathy Trial	P2/P3	unknown	220	Leiden University Medical Center	Sep 2009
NCT00504400		Ranibizumab to Treat Type 2 Idiopathic Macular Telangiectasia (RAMA-Trial)	P2	completed	10	University Hospital, Bonn	Aug 2007
NCT00955630	IVL for OHS	Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularization in Ocular Histoplasmosis Syndrome	P1/P2	unknown	20	Retina Associates of Kentucky	Aug 2009
NCT00433017	AMD	Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)	P2/P3	terminated	255	Novartis	May 2007
NCT00395551		Safety Study of Ranibizumab Eye Injections to Treat Choroidal Neovascularization That Was Caused Other Than by Age-Related Macular Degeneration.	P1	completed	30	Ophthalmic Consultants of Boston	Dec 2005
NCT00499590	COBALT	Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD	P3	terminated	338	OPKO Health, Inc.	Aug 2007
NCT00363168		Ranibizumab in Hemorrhagic Choroidal Neovascularization Trial	P1	completed	7	Johns Hopkins University	Aug 2006
NCT00727038	NVG	Lucentis for New Onset Neovascular Glaucoma	P1/P2	withdrawn	0	University of Illinois at Chicago	Jan 2008
NCT00561834	NAION	Ranibizumab Therapy for Non-arteritic Ischemic Optic Neuropathy	P1	completed	2	University of Colorado, Denver	Nov 2007
NCT00540930		Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy	P4	unknown	400	Shields, Shields and Associates	Apr 2007
NCT00384449		Lucentis (Ranibizumab) for Eales' Disease	P2/P3	completed	1	Oregon Health and Science University	Oct 2006
NCT00500344	CAPTAIN	CAPTAIN:Choroidal Neovascularization Assessment by Pattern Electroretinography	P1	completed	17	Washington University School of Medicine	Jul 2007
NCT00511706	AMD	Safety and Efficacy of a New Treatment as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) Treatment in Patients With Age-Related Macular Degeneration (AMD)	P2	completed	243	Allergan	Nov 2007
NCT00857259		The Efficacy of Oral Everolimus in Patients With Neovascular Age-related Macular Degeneration	P2	terminated	16	Novartis Pharmaceuticals	Feb 2009
NCT00640640	AMD	The Effects of Bevacizumab and Ranibizumab on Ocular Pulse Amplitude in Neovascular Age Related Macular Degeneration (AMD)	N/A	unknown	60	Sheba Medical Center	Aug 2007
NCT00539734		Changes in Retinal Function After Intravitreal Ranibizumab for Age-related Macular Degeneration	N/A	completed	25	Prince of Songkla University	Aug 2007
NCT00395057		A Study Using Intravitreal Injections of a Small Interfering RNA in Patients With Age-Related Macular Degeneration	P2	terminated	138	Allergan	Jan 2007
NCT00387582		Efficacy Study of Lucentis in the Treatment of Diabetic Macular Edema	P2	completed	49	Rocky Mountain Retina Consultants	Jul 2006
NCT00826371	EXTEND II	Evaluation of Safety and Efficacy of Once Monthly Ranibizumab Injections in Chinese Patients With Wet Age Related Macular Degeneration (AMD) Patients	P3	completed	114	Novartis Pharmaceuticals	Jan 2009
NCT00423189		Lucentis Utilizing Visudyne (LUV Trial) Combination Therapy in the Treatment of Age-Related Macular Degeneration	P4	terminated	7	David M. Brown, M.D.	Jan 2007
NCT00284089		Safety and Efficacy of Ranibizumab in Japanese Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration	P1/P2	completed	88	Novartis	Apr 2005
NCT00378196	RIPT	Ranibizumab in Idiopathic Parafoveal Telangiectasia (RIPT) Trial	P1	completed	10	Johns Hopkins University	Sep 2006
NCT00470678	CNV	EXTEND III - Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)	P3	completed	95	Novartis	Jun 2007
NCT00567697		A Randomized Study Comparing Ranibizumab to Sham in Patients With Macular Edema Secondary to CRVO	P3	completed	32	Aleris Helse	Mar 2007
NCT00379795		An Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects With Choroidal Neovascularization Secondary to AMD or Macular Edema Secondary to RVO	N/A	completed	853	Genentech, Inc.	Apr 2005
NCT00516464	PDR	Evaluation of Ranibizumab in Proliferative Diabetic Retinopathy (PDR) Requiring Vitrectomy	P3	unknown	40	Retina Associates, Kansas City	Aug 2007
NCT00710229	MANTA	Manta Study: Avastin Versus Lucentis in Age Related Macular Degeneration	P3	unknown	320	The Ludwig Boltzmann Institute of Retinology and Biomicroscopic Laser Surgery	Jul 2008
NCT00429962		Study Comparing Ranibizumab Monotherapy With Combined Verteporfin Therapy in Subfoveal CNV	P3	completed	40	University Hospital, Basel, Switzerland	Jul 2006
NCT00284050	RESOLVE	Safety and Efficacy of Ranibizumab in Diabetic Macular Edema With Center Involvement	P2	completed	151	Novartis	Oct 2005
NCT00674323	PCV	Efficacy and Safety of Verteporfin Added to Ranibizumab in the Treatment of Symptomatic Macular Polypoidal Choroidal Vasculopathy	P4	completed	61	Novartis	Apr 2008
NCT00331864		SUSTAIN - Study of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration	P3	completed	531	Novartis	Apr 2006
NCT00395707		Study To Determine Safety/Efficacy of Lucentis For Treatment Of Retinal Angiomatous Proliferation Secondary To Age Related Macular Degeneration	P1/P2	completed	20	The National Retina Institute	Aug 2005
NCT00726466	SEIRA	Study of Efalizumab Combined With Intravitreal Ranibizumab in the Treatment of Age-Related Macular Degeneration	P1	withdrawn	0	Vitreous -Retina- Macula Consultants of New York	Mar 2008
NCT00413829	IECOMB	Immediate Effects of Lucentis® in Conjunction With Photodynamic Therapy With Visudyne® in Exudative AMD(IECOMB)	P2	completed	20	Insel Gruppe AG, University Hospital Bern	Oct 2006
NCT00275821	EXCITE	Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)	P3	completed	353	Novartis	Dec 2005
NCT00467935	SALVAGE	Scotoma Reduction in AMD Patients Treated With Ranibizumab	P1/P2	completed	20	Retina Research Foundation	Mar 2007
NCT00570726		Treatment of Failing Blebs With Ranibizumab	P1	completed	6	The New York Eye & Ear Infirmary	Jun 2000
NCT00457145		Injected Ranibizumab to Treat Macular Telangiectasia Without New Blood Vessel Formation	P1	completed	5	National Eye Institute (NEI)	Mar 2007
NCT00457067		Injected Ranibizumab to Treat Macular Telangiectasia With New Blood Vessel Formation	P1	completed	5	National Eye Institute (NEI)	Mar 2007
NCT00251459	CNV	A Study to Evaluate Ranibizumab in Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)	P3	completed	5,000	Genentech, Inc.	Nov 2005
NCT00089765		Ranibizumab Injections to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome	P1	completed	5	National Eye Institute (NEI)	Aug 2004
NCT00288561		Study of Ranibizumab Administered in Conjunction With Photodynamic Therapy With Verteporfin in Patients With Subfoveal Choroidal Neovascularization and Age-Related Macular Degeneration	P2	completed	0	Novartis	Nov 2004
NCT00373659		An OCT-Guided Variable Dosing Regimen With Ranibizumab for the Treatment of Neovascular AMD	P2	completed	40	University of Miami	Aug 2004
NCT00344227		Prospective OCT Study With Lucentis for Neovascular AMD (PrONTO Study)	P2	completed	40	University of Miami	Aug 2004
NCT00090623	AMD	A Study of rhuFab V2 (Ranibizumab) in Subjects With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)	P3	completed	180	Genentech, Inc.	Aug 2004
NCT00403156		Imatinib Mesylate Combined With Intravitreal Ranibizumab in the Treatment of Choroidal Neovascularization Secondary to Age-Related Macular Degeneration	P1	withdrawn	0	Vitreous -Retina- Macula Consultants of New York	Nov 2006
NCT00930189		Comparative Study With Photodynamic Therapy And Triamcinolone Versus Photodynamic Therapy, Triamcinolone And Ranibizumab In Patients With Subfoveal Choroidal Neovascularization	P2/P3	withdrawn	0	Asociación para Evitar la Ceguera en México	Apr 2006
NCT00061594		A Study to Compare rhuFab V2 With Verteporfin Photodynamic in Treating Subfoveal Neovascular Macular Degeneration	P3	completed	426	Genentech, Inc.	May 2003
NCT00967213		Combination of Ranibizumab and Verteporfin Therapy in Neovascular Age-related Macular Degeneration	P3	completed	10	Novartis Korea Ltd.	Aug 2006
NCT00403325		Intravitreal Ranibizumab Treatment of Central Serous Chorioretinopathy	P1	completed	9	Vitreous -Retina- Macula Consultants of New York	Aug 2006
NCT00095433	AMD	Extension Study of rhuFab V2 in Subjects With Neovascular Age-Related Macular Degeneration (AMD)	P3	completed	100	Genentech, Inc.	Sep 2002
NCT00056836		A Study to Evaluate rhuFab V2 in Subjects With Minimally Classic or Occult Subfoveal Neovascular Macular Degeneration	P3	completed	720	Genentech, Inc.	Mar 2003
NCT00056823	AMD	Intravitreal Injections of rhuFab V2 in Combination With Visudyne in Subjects With Age Related Macular Degeneration (AMD)	P1/P2	completed	168	Genentech, Inc.	Mar 2003

Ranibizumab clinical trials: frequently asked questions

How many Ranibizumab clinical trials are there?: 480 Ranibizumab clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 10 are actively recruiting participants. 328 are marked completed.
Are Ranibizumab clinical trials recruiting in 2026?: Yes — 10 Ranibizumab trials are actively recruiting in 2026, with 83 U.S. sites across 26 states. See the recruiting trials and the per-state site list further down this page.
What conditions is Ranibizumab being studied for?: Ranibizumab is being studied for Diabetic Macular Edema, Macular Edema, Macular Degeneration, Age Related Macular Degeneration, Choroidal Neovascularization and 199 more. The trials are grouped by indication on this page.
What phase is Ranibizumab in?: Ranibizumab clinical trials span 96 Phase 4, 110 Phase 3, 95 Phase 2, 42 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors Ranibizumab clinical trials?: The lead sponsor across the most Ranibizumab trials is Novartis Pharmaceuticals, with 251 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Ranibizumabas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed July 17, 2026.

Related pages on Hipa.ai:

Ranibizumab overview Ranibizumab evidence & publications